WO2022138456A1 - ウイルス不活化液状剤およびウイルス不活化物品 - Google Patents
ウイルス不活化液状剤およびウイルス不活化物品 Download PDFInfo
- Publication number
- WO2022138456A1 WO2022138456A1 PCT/JP2021/046578 JP2021046578W WO2022138456A1 WO 2022138456 A1 WO2022138456 A1 WO 2022138456A1 JP 2021046578 W JP2021046578 W JP 2021046578W WO 2022138456 A1 WO2022138456 A1 WO 2022138456A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- virus
- particles
- mxene
- layer
- liquid agent
- Prior art date
Links
- 239000007788 liquid Substances 0.000 title claims abstract description 210
- 239000002245 particle Substances 0.000 claims abstract description 218
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 117
- 239000000463 material Substances 0.000 claims abstract description 32
- 229910052751 metal Inorganic materials 0.000 claims abstract description 27
- 239000002184 metal Substances 0.000 claims abstract description 27
- 229910052799 carbon Inorganic materials 0.000 claims abstract description 22
- 229910052801 chlorine Inorganic materials 0.000 claims abstract description 19
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 13
- 125000001309 chloro group Chemical group Cl* 0.000 claims abstract description 9
- 125000001153 fluoro group Chemical group F* 0.000 claims abstract description 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 8
- 125000004430 oxygen atom Chemical group O* 0.000 claims abstract description 8
- 125000004433 nitrogen atom Chemical group N* 0.000 claims abstract description 7
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract 3
- 241000700605 Viruses Species 0.000 claims description 263
- 230000000415 inactivating effect Effects 0.000 claims description 127
- 239000010936 titanium Substances 0.000 claims description 77
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 66
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 30
- 239000000758 substrate Substances 0.000 claims description 23
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 18
- 239000000460 chlorine Substances 0.000 claims description 18
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 16
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 16
- 229910052794 bromium Inorganic materials 0.000 claims description 16
- 229910044991 metal oxide Inorganic materials 0.000 claims description 14
- 150000004706 metal oxides Chemical class 0.000 claims description 14
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims description 11
- 239000011230 binding agent Substances 0.000 claims description 10
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 claims description 9
- 239000000654 additive Substances 0.000 claims description 8
- 239000002270 dispersing agent Substances 0.000 claims description 8
- 239000003963 antioxidant agent Substances 0.000 claims description 7
- 239000004034 viscosity adjusting agent Substances 0.000 claims description 7
- 230000000996 additive effect Effects 0.000 claims description 6
- 239000003205 fragrance Substances 0.000 claims description 6
- 230000003078 antioxidant effect Effects 0.000 claims 1
- 230000004048 modification Effects 0.000 abstract description 6
- 238000012986 modification Methods 0.000 abstract description 6
- 229910052731 fluorine Inorganic materials 0.000 abstract description 3
- 239000010410 layer Substances 0.000 description 148
- 238000005530 etching Methods 0.000 description 85
- 239000002609 medium Substances 0.000 description 71
- 239000000243 solution Substances 0.000 description 51
- 239000002356 single layer Substances 0.000 description 48
- 238000009830 intercalation Methods 0.000 description 43
- 238000000034 method Methods 0.000 description 42
- 239000006228 supernatant Substances 0.000 description 39
- 230000002687 intercalation Effects 0.000 description 38
- 239000002243 precursor Substances 0.000 description 34
- 230000032798 delamination Effects 0.000 description 31
- 239000000047 product Substances 0.000 description 31
- 238000003756 stirring Methods 0.000 description 29
- 239000002253 acid Substances 0.000 description 28
- 125000004429 atom Chemical group 0.000 description 28
- 239000000203 mixture Substances 0.000 description 27
- 230000002779 inactivation Effects 0.000 description 26
- 238000004519 manufacturing process Methods 0.000 description 26
- 230000003647 oxidation Effects 0.000 description 25
- 238000007254 oxidation reaction Methods 0.000 description 25
- 239000004927 clay Substances 0.000 description 24
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 21
- 239000002002 slurry Substances 0.000 description 17
- 239000007787 solid Substances 0.000 description 17
- 210000004027 cell Anatomy 0.000 description 15
- 238000002360 preparation method Methods 0.000 description 15
- KRHYYFGTRYWZRS-UHFFFAOYSA-N hydrofluoric acid Substances F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 14
- 230000036961 partial effect Effects 0.000 description 14
- 230000008569 process Effects 0.000 description 14
- 238000010306 acid treatment Methods 0.000 description 13
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 12
- 150000001875 compounds Chemical class 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 239000002244 precipitate Substances 0.000 description 12
- 238000002441 X-ray diffraction Methods 0.000 description 11
- 230000000844 anti-bacterial effect Effects 0.000 description 11
- 239000000843 powder Substances 0.000 description 11
- 238000005406 washing Methods 0.000 description 11
- 238000002156 mixing Methods 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 229910052719 titanium Inorganic materials 0.000 description 10
- 238000005119 centrifugation Methods 0.000 description 9
- 241000894006 Bacteria Species 0.000 description 8
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 8
- 239000003242 anti bacterial agent Substances 0.000 description 8
- 238000004140 cleaning Methods 0.000 description 8
- 239000006185 dispersion Substances 0.000 description 8
- 238000011156 evaluation Methods 0.000 description 8
- PQXKHYXIUOZZFA-UHFFFAOYSA-M lithium fluoride Chemical compound [Li+].[F-] PQXKHYXIUOZZFA-UHFFFAOYSA-M 0.000 description 8
- 239000011259 mixed solution Substances 0.000 description 8
- 244000309711 non-enveloped viruses Species 0.000 description 8
- 229910052720 vanadium Inorganic materials 0.000 description 8
- 230000002776 aggregation Effects 0.000 description 7
- 238000010438 heat treatment Methods 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- 229910052750 molybdenum Inorganic materials 0.000 description 7
- 238000004062 sedimentation Methods 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- 238000005054 agglomeration Methods 0.000 description 6
- 229910052804 chromium Inorganic materials 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 6
- 238000012423 maintenance Methods 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- 150000002739 metals Chemical class 0.000 description 6
- 229910052758 niobium Inorganic materials 0.000 description 6
- 230000009471 action Effects 0.000 description 5
- 239000011521 glass Substances 0.000 description 5
- 229910001416 lithium ion Inorganic materials 0.000 description 5
- 150000007522 mineralic acids Chemical class 0.000 description 5
- 238000012545 processing Methods 0.000 description 5
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 5
- 229910052726 zirconium Inorganic materials 0.000 description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 4
- 150000001721 carbon Chemical group 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 229910052735 hafnium Inorganic materials 0.000 description 4
- QPJSUIGXIBEQAC-UHFFFAOYSA-N n-(2,4-dichloro-5-propan-2-yloxyphenyl)acetamide Chemical compound CC(C)OC1=CC(NC(C)=O)=C(Cl)C=C1Cl QPJSUIGXIBEQAC-UHFFFAOYSA-N 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000012224 working solution Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241001678559 COVID-19 virus Species 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 229910010413 TiO 2 Inorganic materials 0.000 description 3
- 239000012736 aqueous medium Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 238000004255 ion exchange chromatography Methods 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 229910052715 tantalum Inorganic materials 0.000 description 3
- 238000009210 therapy by ultrasound Methods 0.000 description 3
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 2
- 235000014469 Bacillus subtilis Nutrition 0.000 description 2
- 241000711573 Coronaviridae Species 0.000 description 2
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 2
- 229910018119 Li 3 PO 4 Inorganic materials 0.000 description 2
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
- 241001263478 Norovirus Species 0.000 description 2
- 239000002033 PVDF binder Substances 0.000 description 2
- 229920001609 Poly(3,4-ethylenedioxythiophene) Polymers 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 238000011053 TCID50 method Methods 0.000 description 2
- MCMNRKCIXSYSNV-UHFFFAOYSA-N Zirconium dioxide Chemical compound O=[Zr]=O MCMNRKCIXSYSNV-UHFFFAOYSA-N 0.000 description 2
- 239000012790 adhesive layer Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 210000000234 capsid Anatomy 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000000120 cytopathologic effect Effects 0.000 description 2
- 239000000645 desinfectant Substances 0.000 description 2
- 238000004993 emission spectroscopy Methods 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
- 230000005660 hydrophilic surface Effects 0.000 description 2
- 238000009616 inductively coupled plasma Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 238000003475 lamination Methods 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 229910052748 manganese Inorganic materials 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 150000002736 metal compounds Chemical class 0.000 description 2
- 230000004660 morphological change Effects 0.000 description 2
- 239000002135 nanosheet Substances 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 229910017604 nitric acid Inorganic materials 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 238000010008 shearing Methods 0.000 description 2
- 235000010413 sodium alginate Nutrition 0.000 description 2
- 239000000661 sodium alginate Substances 0.000 description 2
- 229940005550 sodium alginate Drugs 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 229910052721 tungsten Inorganic materials 0.000 description 2
- 241000712461 unidentified influenza virus Species 0.000 description 2
- 238000004846 x-ray emission Methods 0.000 description 2
- HNSDLXPSAYFUHK-UHFFFAOYSA-N 1,4-bis(2-ethylhexyl) sulfosuccinate Chemical compound CCCCC(CC)COC(=O)CC(S(O)(=O)=O)C(=O)OCC(CC)CCCC HNSDLXPSAYFUHK-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 208000032163 Emerging Communicable disease Diseases 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 241000714201 Feline calicivirus Species 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 241001397616 Influenza A virus (H1N1) Species 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 231100000645 Reed–Muench method Toxicity 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 238000005411 Van der Waals force Methods 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 229910003481 amorphous carbon Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229910052785 arsenic Inorganic materials 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229910052793 cadmium Inorganic materials 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000531 effect on virus Effects 0.000 description 1
- 239000003822 epoxy resin Substances 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- -1 flakes Substances 0.000 description 1
- 229910052733 gallium Inorganic materials 0.000 description 1
- 229910052732 germanium Inorganic materials 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 229910052738 indium Inorganic materials 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000011229 interlayer Substances 0.000 description 1
- 150000008040 ionic compounds Chemical class 0.000 description 1
- 229910052745 lead Inorganic materials 0.000 description 1
- 239000011344 liquid material Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000002923 metal particle Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011812 mixed powder Substances 0.000 description 1
- 238000004264 monolayer culture Methods 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 235000006286 nutrient intake Nutrition 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920000083 poly(allylamine) Polymers 0.000 description 1
- 229920006122 polyamide resin Polymers 0.000 description 1
- 229920000647 polyepoxide Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 238000007639 printing Methods 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229910052706 scandium Inorganic materials 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- GCLGEJMYGQKIIW-UHFFFAOYSA-H sodium hexametaphosphate Chemical compound [Na]OP1(=O)OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])O1 GCLGEJMYGQKIIW-UHFFFAOYSA-H 0.000 description 1
- 235000019982 sodium hexametaphosphate Nutrition 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 238000004528 spin coating Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 230000003746 surface roughness Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 1
- 229910052716 thallium Inorganic materials 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 229910052718 tin Inorganic materials 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- GPPXJZIENCGNKB-UHFFFAOYSA-N vanadium Chemical compound [V]#[V] GPPXJZIENCGNKB-UHFFFAOYSA-N 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 238000004065 wastewater treatment Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
- A01N25/02—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests containing liquids as carriers, diluents or solvents
- A01N25/04—Dispersions, emulsions, suspoemulsions, suspension concentrates or gels
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
- A01N25/34—Shaped forms, e.g. sheets, not provided for in any other sub-group of this main group
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N59/00—Biocides, pest repellants or attractants, or plant growth regulators containing elements or inorganic compounds
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- This disclosure relates to virus inactivated liquid agents and virus inactivated articles.
- Patent Document 1 silver is used as an active ingredient of an antibacterial agent, and an antibacterial layer containing the antibacterial agent and a binder (the water contact angle of a single binder is 20 ° or less) is arranged on a substrate.
- Antibacterial sheets are disclosed.
- Patent Document 1 describes that as an antibacterial agent, an antibacterial agent that exerts a bactericidal effect against pathogenic bacteria such as Staphylococcus aureus and Escherichia coli is preferably used.
- the virus inactivating liquid agent is known to contain alcohol such as ethanol and 2-propanol as an active ingredient.
- the WHO World Health Organization
- the WHO recommends a prescription as a hand sanitizer with an alcohol concentration of 80% by volume ethanol or 75% by volume 2-propanol.
- the effect of virus inactivation can be obtained even with a prescription having an alcohol concentration lower than this.
- the virus inactivating effect can be obtained by prescribing the concentration of ethanol or 2-propanol to 30% by volume with respect to SARS-CoV-2 (so-called "new coronavirus"). It has been reported.
- MXene has been attracting attention as a new material.
- MXene is a kind of so-called two-dimensional material, and is a layered material having the form of one or a plurality of layers as described later.
- MXene has the form of particles of such layered material, which may include powders, flakes, nanosheets, and the like.
- Patent Document 2 discloses an antimicrobial agent containing MXene and an antibacterial membrane in which such an antibacterial agent is coated on a substrate of polyvinylidene fluoride (PVDF). Patent Document 2 describes that such an antibacterial agent has an antibacterial effect against each bacterium of Escherichia coli (E. coli) and Bacillus subtilis (B. subtilis).
- PVDF polyvinylidene fluoride
- bacteria are unicellular organisms, have micron-order sizes, and are capable of self-propagation.
- viruses are composed of nucleic acids (genes) and capsids, and optionally envelopes, have a size on the order of nanometers, are unable to self-proliferate, and parasitize cells (hosts) to multiply.
- bacteria and viruses are quite different, at least in terms of structure, size and growth mechanism. Even if a substance exhibits an antibacterial effect, it cannot be determined by itself whether or not the substance exhibits a virus inactivating effect.
- Patent Documents 1 and 2 make no mention of viruses.
- the antibacterial property can be evaluated according to JIS Z 2801 as described in Patent Document 1, for example.
- the virus inactivating ability can be evaluated by the TCID 50 method, for example, as described in Non-Patent Document 1, although there is no specific standard.
- the purpose of the present disclosure is to provide a novel virus inactivating liquid agent and a virus inactivating article.
- MXene has a virus inactivating ability, and have completed the present disclosure.
- a virus inactivating liquid agent comprising a liquid medium and particles of a layered material comprising one or more layers.
- the layer has the following formula: M m X n (In the formula, M is at least one group 3, 4, 5, 6, 7 metal, and X is a carbon atom, a nitrogen atom or a combination thereof, n is 1 or more and 4 or less, m is greater than n and less than or equal to 5)
- T is at least one selected from the group consisting of hydroxyl groups, fluorine atoms, chlorine atoms and oxygen atoms).
- the MmXn may be Ti 3 C 2 .
- the average thickness of the particles may be 10 nm or less.
- the liquid medium may contain at least one of water and alcohol.
- the virus inactivating liquid agent further comprises at least one additive selected from the group consisting of dispersants, binders, antioxidants, viscosity modifiers and fragrances. obtain.
- the content of the particles in the virus inactivating liquid agent may be 0.5 mg / mL or more and 100 mg / mL or less.
- the pH of the liquid medium may be 2.7 or more and 7.0 or less.
- the Li content in the particles may be 20 mass ppm or less.
- the total content of chlorine and bromine in the particles may be 1500 mass ppm or less.
- the particles may carry at least one of a metal and a metal oxide.
- the particles may carry titanium oxide.
- the virus inactivated layer comprises a virus inactivated layer disposed on the substrate, and the virus inactivated layer contains particles of a layered material containing one or more layers.
- the layer has the following formula: M m X n (In the formula, M is at least one group 3, 4, 5, 6, 7 metal, and X is a carbon atom, a nitrogen atom or a combination thereof, n is 1 or more and 4 or less, m is greater than n and less than or equal to 5)
- M is at least one group 3, 4, 5, 6, 7 metal
- X is a carbon atom, a nitrogen atom or a combination thereof, n is 1 or more and 4 or less, m is greater than n and less than or equal to 5
- T is at least one selected from the group consisting of hydroxyl groups, fluorine atoms, chlorine atoms and oxygen atoms.
- the substrate may be selected from the group consisting of filters, masks, face shields, bandages, gloves, gowns, touch panels, displays, films and seals. ..
- the MmXn may be Ti 3 C 2 .
- the average thickness of the particles may be 10 nm or less.
- the virus inactivated article may further comprise at least one additive selected from the group consisting of dispersants, binders, antioxidants, viscosity modifiers and fragrances. ..
- the Li content in the particles may be 20 mass ppm or less.
- the total content of chlorine and bromine in the particles may be 1500 mass ppm or less.
- the particles may carry at least one of a metal and a metal oxide.
- the particles may carry titanium oxide.
- the virus inactivating liquid agent and the virus inactivating layer of the virus inactivating article contain particles of a predetermined layered material (also referred to as "MXene” herein), whereby the virus. Can be inactivated. Therefore, according to the present disclosure, a novel virus inactivating liquid agent and a virus inactivating article are provided.
- FIG. 6 is a schematic schematic cross-sectional view showing MXene, a layered material that can be used in one embodiment of the present disclosure, where (a) shows a single layer MXene and (b) is a multi-layer (exemplarily two-layer) MXene. show. It is a figure explaining the virus inactivated article in one Embodiment of this disclosure, (a) shows the schematic schematic cross-sectional view of the virus inactivated article, (b) is the virus inactivated layer in the virus inactivated article. A schematic perspective view of the layered material is shown.
- Example 2 is an SEM photograph showing that partial oxidation is proceeding in the heat treatment (oxidation treatment) of Example 2, (a) is an SEM photograph of solid content (particles) before treatment, and (b) is treatment. It is an SEM photograph of the later solid content (particle).
- Embodiment 1 Virus inactivating liquid agent
- the virus inactivating liquid agent in one embodiment of the present disclosure will be described in detail, but the present disclosure is not limited to such an embodiment.
- the virus inactivating liquid agent of the present embodiment contains a liquid medium and particles of a predetermined layered material.
- the predetermined layered material that can be used in this embodiment is MXene and is defined as follows: A layered material comprising one or more layers, wherein the layer has the following formula: M m X n (In the formula, M is at least one group 3, 4, 5, 6, 7 metal, so-called early transition metals such as Sc, Ti, Zr, Hf, V, Nb, Ta, Cr, Mo and It may contain at least one selected from the group consisting of Mn.
- the layer body represented by may have a crystal lattice in which each X is located in an octahedral array of M) and the surface of the layer body (more specifically, facing each other of the layer body).
- a layered material containing a modification or termination T (T is at least one selected from the group consisting of hydroxyl groups, fluorine atoms, chlorine atoms and oxygen atoms) present on at least one of the two surfaces.
- n can be 1, 2, 3 or 4, but is not limited to this.
- M is preferably at least one selected from the group consisting of Ti, Zr, Hf, V, Nb, Ta, Cr, Mo and Mn, and from Ti, V, Cr and Mo. More preferably, it is at least one selected from the group.
- M can be titanium or vanadium and X can be a carbon atom or a nitrogen atom.
- the MAX phase is Ti 3 AlC 2 and MXene is Ti 3 C 2 T s (in other words, M is Ti, X is C, n is 2 and m is 3). Is). That is, the above equation: Mm Xn is Ti 3 C 2 .
- MXene particles are synthesized by selectively etching (removing and optionally layering) A atoms (and optionally a part of M atoms) from the MAX phase. be able to.
- the MAX phase is as follows: M m AX n (In the formula, M, X, n and m are as described above, A is at least one group 12th, 13th, 14th, 15th and 16th element, usually a group A element, representatively.
- Is a group IIIA and a group IVA may include at least one selected from the group consisting of Al, Ga, In, Tl, Si, Ge, Sn, Pb, P, As, S and Cd.
- a layer composed of A atoms is located between two layers represented by and represented by Mm Xn (each X may have a crystal lattice located in an octahedral array of M ). It has a crystal structure.
- Mm Xn Mm Xn
- a atom layer a layer of A atoms
- the A atom layer (and possibly part of the M atom) is removed by selectively etching (removing and possibly layering) the A atom (and possibly part of the M atom) from the MAX phase.
- the surface of the exposed MmXn layer is modified with hydroxyl groups, fluorine atoms, chlorine atoms, oxygen atoms, etc. present in the etching solution (usually, but not limited to, an aqueous solution of fluoroacid is used). , Terminate such a surface.
- the above etching is performed using an acid such as HF, HCl, HBr, HI, sulfuric acid, phosphoric acid, and nitric acid using a fluorine-based resin container.
- an acid such as HF, HCl, HBr, HI, sulfuric acid, phosphoric acid, and nitric acid using a fluorine-based resin container.
- it can be carried out using an etching solution containing F ⁇ , and may be, for example, a method using a mixed solution of lithium fluoride and hydrochloric acid, a method using hydrofluoric acid, or the like.
- any suitable metal for example, Li
- the intercalation treatment may be performed separately after the etching treatment or may be performed in combination with the etching treatment.
- any suitable post-treatment may facilitate the layer separation of MXene (delamination, separation of multilayer MXene into single layer MXene).
- a mechanical shaker, a vortex mixer, a homogenizer, an ultrasonic bath, or the like can be used to perform delamination processing for a predetermined time.
- the supernatant and the precipitate are separated by a centrifuge, and the recovered supernatant can be obtained as a dispersion of single-layered MXene particles.
- the shearing force is too large and the MXene can be destroyed.
- MXene particles having a two-dimensional shape preferably single-layer MXene particles having a larger aspect ratio
- a hand is used. It is preferable to apply an appropriate shearing force by shaking or an automatic shaker.
- the MXene particles may contain a relatively small amount of residual A atom, for example, 10% by mass or less with respect to the original A atom.
- the residual amount of A atom can be preferably 8% by mass or less, more preferably 6% by mass or less.
- the residual amount of A atom exceeds 10% by mass, there may be no problem depending on the use and usage conditions of virus inactivation.
- the MXene particles 10 thus synthesized are particles of a layered material containing one or more MXene layers 7a, 7b (as an example of the MXene particles 10, FIG. 1 (a), as schematically shown in FIG. ) Shows one layer of MXene particles 10a, and FIG. 1B shows two layers of MXene particles 10b, but is not limited to these examples). More specifically, the MXene layers 7a and 7b are formed on the surfaces of the layer bodies ( MmXn layer) 1a and 1b represented by MmXn and the layer bodies 1a and 1b (more specifically, in each layer). It has modifications or terminations T 3a, 5a, 3b, 5b that are present on at least one of the two surfaces facing each other.
- the MXene layers 7a and 7b are also expressed as "MM X n T s ", and s is an arbitrary number.
- the MXene particles 10 include a plurality of MXene layers even if the MXene layers are individually separated and exist in one layer (a single-layer structure shown in FIG. 1A, so-called single-layer MXene particles 10a). May be a laminated body (multilayer structure shown in FIG. 1B, so-called multi-layer MXene particles 10b) in which the particles are laminated apart from each other, or a mixture thereof.
- the MXene particles 10 can be particles (which may also be referred to as powder or flakes) as an aggregate composed of single-layer MXene particles 10a and / or multilayer MXene particles 10b.
- multi-layer MXene particles two adjacent MXene layers (eg, 7a and 7b) may not necessarily be completely separated or may be partially in contact.
- the MXene particles 10 have as many single-layer MXene particles as possible (the content ratio of the single-layer MXene particles is high) as compared with the multilayer MXene particles.
- the thickness of each layer (corresponding to the above MXene layers 7a and 7b) in the MXene particles is, for example, 0.8 nm or more and 5 nm or less, particularly 0.8 nm or more and 3 nm or less (corresponding to the above-mentioned MXene layers 7a and 7b).
- the maximum dimension in a plane parallel to the layer (two-dimensional sheet surface) is, for example, 0.1 ⁇ m or more and 200 ⁇ m or less, particularly 1 ⁇ m or more and 40 ⁇ m or less.
- the interlayer distance is, for example, 0.8 nm or more and 10 nm or less, particularly, for each laminated body. It is 0.8 nm or more and 5 nm or less, more particularly about 1 nm, and the maximum dimension in a plane (two-dimensional sheet surface) perpendicular to the stacking direction is, for example, 0.1 ⁇ m or more and 100 ⁇ m or less, particularly 1 ⁇ m or more and 20 ⁇ m or less.
- the total number of layers in the MXene particles may be 1 or 2 or more, but is, for example, 1 or more and 100,000 or less, particularly 1,000 or more and 20,000 or less, and the thickness in the stacking direction is, for example, 0.1 ⁇ m or more. It is 200 ⁇ m or less, particularly 1 ⁇ m or more and 40 ⁇ m or less.
- the MXene particles When the MXene particles are laminated (multilayer MXene) particles, it is preferable that the MXene particles have a small number of layers.
- the term "small number of layers” means, for example, that the number of stacked MXene particles is 6 or less.
- the thickness of the multilayer MXene particles having a small number of layers in the stacking direction is preferably 10 nm or less. In the present specification, this "multilayer MXene with a small number of layers" (multilayer MXene in a narrow sense) is also referred to as "small layer MXene".
- the MXene particles are preferably particles (which may also be referred to as nanosheets), most of which are composed of single-layer MXene and / or small-layer MXene.
- the single layer MXene and the small layer MXene may be collectively referred to as "single layer / small layer MXene”.
- the average thickness of MXene particles is preferably 10 nm or less.
- the average value of this thickness is more preferably 7 nm or less, and even more preferably 5 nm or less.
- the lower limit of the thickness of the MXene particles can be 1.0 nm. Therefore, the average value of the thickness of MXene particles can be 1 nm or more.
- the proportion of particles (single-layer MXene particles and / or small-layer MXene particles) having a thickness of 10 nm or less in the stacking direction in the entire MXene particles is preferably 90% by volume or more, more preferably. Is 95% by volume or more.
- these dimensions described above are number average dimensions (for example, at least 40 number averages) or X-rays based on photographs of a scanning electron microscope (SEM), a transmission electron microscope (TEM), or an interatomic force microscope (AFM). It is obtained as the distance in the real space calculated from the position on the inverted lattice space of the (002) plane measured by the diffraction (XRD) method.
- SEM scanning electron microscope
- TEM transmission electron microscope
- AFM interatomic force microscope
- the liquid medium may be an aqueous medium.
- the aqueous medium is typically water, and in some cases, contains other liquid substances in a relatively small amount (for example, 30% by mass or less, preferably 20% by mass or less based on the whole aqueous medium) in addition to water. May be good.
- the liquid medium can be understood as a dispersion medium capable of dispersing MXene particles. Solutes such as ions may be dissolved in the liquid medium.
- the liquid medium may contain at least one of water and alcohol.
- the liquid medium is preferably water or a mixture of water and alcohol.
- the alcohol is not particularly limited, but may be, for example, methanol, ethanol, propanol (1-propanol, 2-propanol) or the like.
- an alcohol methanol, ethanol, propanol, etc.
- the content of alcohol in the liquid medium as a whole is not particularly limited and is virus-free. It can be appropriately selected depending on the mode of use of the activating liquid agent and the like.
- the liquid medium is preferably water, or a mixture of water and a relatively small amount of alcohol, more preferably water. preferable.
- Water is nonflammable and does not have the flammable / flammable risk of alcohol.
- the flash point can be within the normal temperature range and ignition, although it depends on the type and concentration of alcohol. There is a risk of ignition if there is a source.
- the virus inactivating liquid agent of the present embodiment may further contain other components.
- the virus inactivating liquid may further contain at least one additive selected from the group consisting of dispersants, binders, antioxidants, viscosity modifiers and fragrances.
- Dispersants can be added to enhance the dispersibility of MXene particles in the liquid medium.
- the binder is formed by applying a virus inactivating liquid agent to an object and drying it (at least partially removing the liquid medium), and then the MXene particles and the object (base material in the case of Embodiment 2 described later). It can be added to increase the adhesion strength between the spaces or to increase the strength of the virus inactivating layer itself, which can be formed from the virus inactivating liquid.
- Antioxidants can be added where it is desired to prevent the oxidation of MXene particles, more specifically the oxidation of the metal (M) constituting the MXene layer.
- the viscosity modifier can be added to adjust the viscosity of the virus inactivated liquid. More specific examples of additives include polyurethane (PU), polyvinyl alcohol (PVA), polyethylenedioxythiophene (PEDOT), sodium alginate (SA), polyamide resin (eg nylon), epoxy resin, acrylic. Examples thereof include resins, sodium hexametaphosphate, polyallylamine and the like.
- Such other components may be added / mixed at any suitable time in the process of manufacturing the virus inactivated liquid.
- other components can be added to a mixture (typically a slurry) containing the synthesized MXene particles in a liquid medium, or to the synthesized MXene particles (typically clay or powder). Can be added with a liquid medium.
- the virus inactivating liquid agent of the present embodiment contains MXene particles having a virus inactivating ability as an active ingredient. It is a finding uniquely obtained by the present inventors that MXene particles have a virus inactivating ability.
- MXene particles have a modified or terminated T (T is at least one selected from the group consisting of hydroxyl groups, fluorine atoms, chlorine atoms and oxygen atoms) on the surface of the layer body represented by MmXn . However, there are sites that are charged (negative or positive) due to this configuration.
- MXene particles can be negatively charged at the plane (two-dimensional sheet surface) portion parallel to the layer and positive at the ends of the layer of MXene particles. Can be charged.
- viruses can also have a charge (eg, a positive charge) and are adsorbed by Coulomb force to the opposite charged (eg, negative) sites present in MXene particles. Since the MXene particles are conductive, when the virus is adsorbed on the site of the MXene particles, the virus is electrically neutralized, resulting in immediate inactivation of the virus.
- MXene particles inactivate a virus is fundamentally different from the mechanism by which MXene particles exhibit an antibacterial effect (suppress the growth of bacteria).
- Bacteria have a size similar to or larger than MXene particles. Therefore, the bacterium is surrounded by a plurality of MXene particles (rather than being adsorbed by the MXene particles like a virus). In such a state, the effect of a specific site of MXene particles on bacteria is very small (compared to the effect on viruses).
- bacteria have a cell wall and a cell membrane, they are not unable to grow immediately by being surrounded by a plurality of MXene particles, but are gradually suppressed from growing by inhibiting life-sustaining activities such as nutrient intake. ..
- the MXene particles are preferably single-layer / small-layer MXene particles, and the average thickness of the MXene particles is preferably 10 nm or less.
- the virus is not particularly limited.
- the virus can be composed of nucleic acids (genes) and capsids, and optionally envelopes, and can generally have a size on the order of nanometers, eg, tens to hundreds of nm.
- enveloped viruses viruses with envelopes
- examples of enveloped viruses include SARS-CoV-2 (so-called "new corona virus"), influenza virus, herpes virus, ruin virus, hepatitis B virus, hepatitis C virus, AIDS virus, etc.
- non-enveloped viruses include norovirus, rotavirus, poliovirus, adenovirus and the like. In the evaluation test of virus inactivating ability, feline calicivirus can be used as a substitute virus for norovirus.
- virus inactivation means that the infectivity of the virus is lost, and may also be expressed as "antivirus”. Specifically, when the virus infectivity is evaluated by the TCID 50 method, if the virus infectivity is below the detection limit, it may be considered that "virus inactivation” has been achieved. It can be understood that the ability to inactivate a virus (the ability to inactivate a virus) is higher as the duration of action required for the virus infectivity to fall below the detection limit is shorter.
- the "liquid agent” means a drug having a liquid form as a whole.
- the liquid agent may be a dispersion (or suspension) in which MXene particles are dispersed (or suspended) in a liquid medium, and depending on the usage mode of the virus inactivating liquid agent, for example, a sprayable slurry or a dispenser. It may be a possible gel or the like.
- the virus inactivating liquid agent of the present embodiment has a high virus inactivating ability, and can inactivate a virus in, for example, 1 minute or a short action time.
- the virus inactivating liquid agent of the present embodiment contains MXene particles as an active ingredient, MXene particles even if the liquid medium is volatilized by being exposed to air after applying the virus inactivating liquid agent to the object. Remains on the surface of the object and can exert the effect of virus inactivation continuously for a long period of time, for example, even after 24 hours.
- a conventional general alcohol-based disinfectant if the alcohol volatilizes, the effect of virus inactivation cannot be obtained.
- the virus inactivating liquid agent of the present embodiment shows a sufficient virus inactivating effect even if the content of MXene particles as an active ingredient is small.
- the content of MXene particles in the virus inactivating liquid agent can be, for example, 0.5 mg / mL or more, preferably 1 mg / mL or more, and more preferably 5 mg / mL or more.
- the upper limit of the content of MXene particles in the virus inactivating liquid agent can be appropriately selected depending on the usage mode of the virus inactivating liquid agent and the like, but when a dilute virus inactivating liquid agent is desired, the above content is used. For example, it can be 100 mg / mL or less, 50 mg / mL or less if necessary, and 10 mg / mL or less if further required.
- the pH of the liquid medium can be appropriately selected depending on the characteristics and applications desired for the virus inactivating liquid agent, and is, for example, 2.7 or more and 7.0 or less. obtain.
- MXene particles can be stably dispersed in a liquid medium, and aggregation and / or sedimentation of MXene particles can be prevented or reduced.
- Dispersion stability is the use of a virus inactivating liquid (applying to an object) and / or the desired virus inactivating effect of the virus inactivating liquid (or virus inactivation formed with it). It is important to obtain evenly over the entire layer.
- the pH of the liquid medium is preferably 2.7 or more and 6.0 or less.
- the pH of the liquid medium is preferably 3.0 or more and 5.0 or less.
- the effect of virus inactivation can be continuously exerted for a longer period of time.
- the present disclosure is not bound by any theory, it is considered that the oxidation of MXene particles is stabilized in the pH range of 3.0 or more and 5.0 or less, whereby the above-mentioned effects can be obtained.
- MXene particles can undergo hydrolysis from the ends of the MXene layer and can form oxides of the metals (M) that make up the MXene layer (eg, Ti 3 C 2 T s ).
- MXene particles represented by, TiO 2 can be produced, and CH 4 and / or amorphous carbon can be produced as a by-product). That is, the MXene particles are chemically decomposed in the portion where the oxidation has occurred without maintaining the MmXn of the layer body, and are coated with the oxide of the metal ( M ) (hereinafter,). Such partial oxidation is also simply referred to as "partial oxidation"). Even if some partial oxidation occurs in the MXene particles, not all of the charged sites of the MXene particles are lost, so that the effect of virus inactivation is not significantly inactivated.
- partial oxidation of MXene particles may occur to some extent, but the oxidation is stabilized (in other words, apparently, the oxidation does not proceed substantially). It is possible to prevent the effect of virus inactivation from being completely inactivated, and it can be exerted continuously for a longer period of time at a level sufficient for virus inactivation. Further, it is considered that the fact that the decomposition of MXene particles does not apparently proceed due to the stabilization of oxidation as described above also contributes to the acquisition of high dispersion stability.
- the pH of the liquid medium can be adjusted by the type and concentration of ions dissolved in the liquid medium. Not limited to this embodiment, but for example, depending on the treatment conditions for etching and / or intercalation (eg, acid and / or base type and charge concentration), a virus-inactivating liquid agent subsequently obtained (for example). Typically, the pH of the liquid medium in the slurry after delamination) can be adjusted. As described above, the intercalation treatment may be performed separately after the etching treatment or may be performed in combination with the etching treatment. Further, for example, when the synthesized MXene particles (typically clay or powder obtained by separating as solids after washing with water) are mixed with the liquid medium, the pH of the liquid medium may be adjusted in advance. can.
- a virus-inactivating liquid agent subsequently obtained (for example).
- the pH of the liquid medium in the slurry after delamination can be adjusted.
- the intercalation treatment may be performed separately after the etching treatment or may be performed in combination with the
- the Li content in MXene particles is preferably 20% by mass or less. It is known that Li can affect a living body when it is present in a relatively large amount, but the virus-inactivating liquid agent according to this embodiment has a Li content of 20% by mass or less in MXene particles. Therefore, it may have high biocompatibility.
- the lower limit of the Li content in the MXene particles is not particularly limited and may be zero.
- the content of Li in MXene particles can be suppressed to 20% by mass or less.
- the Li content in the MXene particles can be, for example, 1 mass ppm or more.
- the virus inactivated liquid agent in which the Li content is suppressed can be produced, for example, by the following first production method or second production method.
- the first method for producing a virus-inactivated liquid agent is (A) Preparing a precursor composed of the MAX phase, (B1) Using an etching solution, an etching process for removing at least a part of A atoms from the precursor is performed. (C) Performing a Li intercalation treatment including a step of mixing and stirring the etched product obtained by the etching treatment and the Li-containing compound. (D) A delamination treatment including a step of centrifuging the Li intercalation-treated product obtained by the Li intercalation treatment, discarding the supernatant liquid, and then washing the remaining precipitate with water is performed.
- Performing an acid treatment which comprises a step of mixing and stirring the delamination-treated product obtained by the delamination treatment and an acid solution.
- the acid-treated product obtained by acid treatment is washed with water to obtain MXene particles, and
- the obtained MXene particles are mixed with a liquid medium to obtain a virus-inactivated liquid agent. Including that.
- a virus inactivating liquid agent having a Li content of 0.0020% by mass (20% by mass) or less in MXene particles can be produced.
- the second method for producing a virus-inactivated liquid agent is (A) Preparing a precursor composed of the MAX phase, (B2) Etching at least a part of A atoms from the precursor using an etching solution containing a Li-containing compound, and performing Li intercalation treatment. (D) The step of centrifuging the treated product obtained by the etching and Li intercalation treatment (etching + Li intercalation), discarding the supernatant liquid, and then washing the remaining precipitate with water is included. Performing lamination processing, (E) Performing an acid treatment, which comprises a step of mixing and stirring the delamination-treated product obtained by the delamination treatment and an acid solution.
- the acid-treated product obtained by acid treatment is washed with water to obtain MXene particles, and (g) the obtained MXene particles are mixed with a liquid medium to obtain a virus-inactivated liquid agent. Including that.
- a virus inactivating liquid agent having a Li content of 0.0020% by mass (20% by mass) or less in MXene particles can be produced.
- a precursor composed of the MAX phase is prepared.
- the MAX phase is as described above.
- the precursor may contain trace impurities inevitably mixed in addition to the MAX phase.
- an etching process is performed in which at least a part of A atoms is removed from the precursor using an etching solution.
- the etching treatment conditions are not particularly limited, and known conditions can be adopted.
- Etching can be carried out using an etching solution containing F ⁇ , for example, a method using fluorine, a method using a mixed solution of lithium fluoride and hydrochloric acid, and an etching solution further containing phosphoric acid or the like.
- the method that was used is mentioned. Examples of these methods include a method using a mixed solution with pure water as a solvent.
- Examples of the etched product obtained by the above etching treatment include a slurry.
- Step (c) A Li intercalation treatment including a step of mixing and stirring the etched product obtained by the etching treatment and the Li-containing compound is performed.
- Li-containing compound examples include metal compounds containing Li ions.
- the metal compound containing Li ion an ionic compound in which Li ion and cation are bonded can be used. Examples thereof include iodide, phosphates, sulfides including sulfates, nitrates, acetates and carboxylates of Li ions.
- the content of the Li-containing compound in the intercalation treatment formulation is preferably 0.001% by mass or more.
- the content is more preferably 0.01% by mass or more, still more preferably 0.1% by mass or more.
- the content of the Li-containing compound is preferably 10% by mass or less, more preferably 1% by mass or less.
- step (c) for example, the slurry obtained by the etching treatment in the above step (b1) is washed by repeating centrifugation-removal of the supernatant liquid-adding pure water to the remaining precipitate-recentrifugation.
- the Moisture Medium Clay of MXene may be subjected to an intercalation treatment as an etching treated product.
- the specific method of the intercalation treatment is not particularly limited, and examples thereof include mixing a Li-containing compound with the above-mentioned MXene water medium clay and stirring at room temperature.
- the etching treatment of the precursor and the Li intercalation treatment are performed together.
- ⁇ Process (b2) In the second production method, at least a part of A atom (and a part of M atom in some cases) is etched (removed and optionally layer-separated) from the precursor using an etching solution containing a Li-containing compound. , Li etching processing is performed.
- step (b2) Li ions are inserted between the layers of the MmXn layer during etching (removal and optionally layer separation) of at least some A atoms (and possibly some M atoms) from the MAX phase. Li intercalation processing is performed.
- the content of the Li-containing compound in the etching solution is preferably 0.001% by mass or more.
- the content is more preferably 0.01% by mass or more, still more preferably 0.1% by mass or more.
- the content of the Li-containing compound in the etching solution is preferably 10% by mass or less, more preferably 1% by mass or less.
- the etching solution in the step (b2) may contain a Li-containing compound, and other configurations of the etching solution are not particularly limited, and known conditions can be adopted.
- it can be carried out using an etching solution further containing F ⁇ , for example, a method using hydrofluoric acid, a method using a mixed solution of lithium fluoride and hydrochloric acid, and further.
- Examples thereof include a method using an etching solution containing phosphoric acid and the like. Examples of these methods include a method using a mixed solution with pure water as a solvent.
- Examples of the etched product obtained by the above etching treatment include a slurry.
- Step (d) Centrifuge the Li intercalation-treated product obtained by the Li intercalation treatment in the first manufacturing method, or the (etching + Li intercalation) treated product obtained by the etching and Li intercalation treatment in the second manufacturing method.
- a delamination treatment is performed, which comprises the step of separating, discarding the supernatant and then washing the remaining precipitate with water.
- the conditions for the delamination process are not particularly limited and can be performed by a known method. For example, the method shown below may be used.
- the supernatant may be centrifuged, the supernatant after centrifugation may be discarded, and a single-layer / small-layer MXene-containing clay before acid treatment may be obtained as a delamination-treated product.
- a step of mixing and stirring a delamination-treated product (single-layer / small-layer MXene-containing supernatant liquid or single-layer / small-layer MXene-containing clay) obtained by the delamination treatment and an acid solution is included.
- Perform acid treatment The acid used for the acid treatment is not limited, and for example, an inorganic acid such as a mineral acid and / or an organic acid can be used.
- the acid is preferably only an inorganic acid or a mixed acid of an inorganic acid and an organic acid.
- the acid is more preferably only an inorganic acid.
- the inorganic acid for example, one or more of hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, perchloric acid, hydroiodic acid, hydrobromic acid, hydrofluoric acid and the like can be used. It is preferably one or more of hydrochloric acid and sulfuric acid.
- the organic acid include acetic acid, citric acid, oxalic acid, benzoic acid, and sorbic acid.
- the concentration of the acid solution to be mixed with the delamination-treated product may be adjusted according to the amount and concentration of the delamination-treated product to be treated.
- the delamination-treated product and the acid solution are mixed and stirred.
- the stirring method include stirring using a handshake, an automatic shaker, a share mixer, a pot mill, and the like.
- the degree of stirring such as the stirring speed and the stirring time may be adjusted according to the amount and concentration of the delamination-treated product to be treated.
- the acid solution When the above acid solution is mixed and stirred, it does not matter whether it is heated or not.
- the acid solution may be mixed and stirred without heating, or may be stirred while heating within a range where the liquid temperature is 80 ° C. or lower.
- centrifugation can be performed to remove the supernatant liquid, and an acid-treated product can be obtained as a slurry.
- the operation of mixing with the acid solution and stirring may be performed at least once. From the viewpoint of reducing the Li content in the MXene particles, it is preferable to perform the operation of mixing with the acid solution and stirring the mixture twice or more, for example, 10 times or less.
- the operation of mixing with the acid solution and stirring is performed a plurality of times, (i) the acid solution (with the delamination-treated product or the remaining precipitate obtained in (iii) below) is mixed and stirred.
- the steps (i) to (iii) of (ii) centrifuging the agitated material and (iii) discarding the supernatant after centrifugation may be performed twice or more, for example, 10 times or less.
- the pH of the acid-treated product obtained by the acid treatment is preferably 2.5 or less.
- the pH is more preferably 2.0 or less, still more preferably 1.5 or less, still more preferably 1.2 or less.
- the lower limit of pH is not particularly limited, but is about 1.0.
- the acid-treated product obtained by acid treatment is washed with water to obtain MXene particles.
- the amount of water to be mixed with the acid-treated product and the cleaning method are not particularly limited.
- water may be added for stirring, centrifugation and the like.
- the stirring method include stirring using a handshake, an automatic shaker, a share mixer, a pot mill, and the like.
- the degree of stirring such as the stirring speed and the stirring time may be adjusted according to the amount and concentration of the acid-treated product to be treated.
- the washing with water may be performed at least once. It is preferable to wash with water a plurality of times.
- ⁇ Process (g) The MXene particles obtained as described above are mixed with a liquid medium to obtain a virus-inactivated liquid agent.
- the details of the liquid medium are as described above.
- the liquid medium is water
- the water used in the washing in the step (f) (the water used in the final washing when the washing with water is performed twice or more) is the liquid medium used in the step (g). It may also serve as.
- the pH of the liquid medium can be 2.7 or more and 7.0 or less, preferably 2.7 or more and 6.0 or less, more preferably 3.0, as described above. It is 5.0 or more and 5.0 or less.
- a virus inactivating liquid agent having a Li content of 20% by mass or less in MXene particles can be produced.
- the Li content in MXene particles can be measured by elemental (atomic) analysis such as inductively coupled plasma emission spectroscopy (ICP-AES) or X-ray fluorescence spectrometry (XRF).
- elemental analysis such as inductively coupled plasma emission spectroscopy (ICP-AES) or X-ray fluorescence spectrometry (XRF).
- the total content of chlorine and bromine in MXene particles is preferably 1500 mass ppm or less.
- the content of chlorine and bromine among halogens is suppressed to a certain level or less, that is, so-called "halogen-free". Since the virus inactivating liquid agent of the present embodiment suppresses the total content of chlorine and bromine in MXene particles, it can be suitably used for applications requiring halogen-free.
- the total content of chlorine and bromine is preferably 900 mass ppm or less, and most preferably 0 mass ppm or less.
- the lower limit of the total content of chlorine and bromine in MXene particles is not particularly limited and may be zero.
- a virus inactivated liquid agent in which the total content of chlorine and bromine is suppressed can be produced, for example, by the following third production method.
- the third method for producing a virus-inactivated liquid agent is (A) Preparing a precursor composed of the MAX phase, (B3) Etching of A atom from the precursor using an etching solution, wherein the etching solution has an H 3 PO 4 concentration of 5.5 M or more, a HI concentration of 5.0 M or more, and H 2 It comprises satisfying at least one selected from the group consisting of SO 4 concentration of 5.0 M or more, and (g3) mixing the obtained MXene particles with a liquid medium to obtain a virus inactivating liquid agent.
- a precursor composed of the MAX phase is prepared. This step is the same as the first manufacturing method and the second manufacturing method.
- An etching solution is used to etch (remove and optionally layer) A atoms (and possibly some M atoms) from the precursor.
- an etching solution satisfying at least one selected from the group consisting of an H 3 PO 4 concentration of 5.5 M or more, a HI concentration of 5.0 M or more, and an H 2 SO 4 concentration of 5.0 M or more. Use.
- step (b3) the A atom (and optionally a portion of the M atom) from the MAX phase is present in the etching solution on the surface of the exposed MmXn layer after etching (removal and possibly layer separation).
- At least one selected from the group consisting of PO 4 3- , I, and SO 4-2 is adsorbed and bound. It is considered that when these PO 4 3- and the like are adsorbed on the surface of the Mm Xn layer, the distance between the MXene layers is widened due to steric hindrance, and the van der Waals force between the Mm Xn layers is weakened.
- the MmXn layer can be easily made into a single layer without applying strong shear to the multi-layered MmXn layer. Further, since it is not necessary to apply strong shear, the fracture of the MmXn layer in the plane is suppressed, and as a result, a single MmXn layer having a large two-dimensional surface can be obtained.
- the above etching solution does not contain hydrochloric acid, that is, does not contain chlorine atoms.
- chlorine atom-free in the etching solution means that the chlorine concentration in the etching solution is 10 mass ppm or less when measured by, for example, combustion-ion chromatography.
- the etching solution does not contain hydrochloric acid and may contain at least one of the above-mentioned predetermined amounts of H 3 PO 4 , etc., and other configurations of the etching solution are not particularly limited, and known conditions may be adopted. can. For example, it can be carried out using an etching solution further containing F ⁇ , and examples thereof include a method using a mixed solution of hydrofluoric acid (HF) and at least one of the above-mentioned predetermined amounts of H 3 PO 4 .
- the concentration of hydrofluoric acid in this mixed solution may be 1% by mass or more and 50% by mass or less.
- the H 3 PO 4 concentration is 13.2 M or less, and the HI concentration. Can be 6.5 M or less, and the H 2 SO 4 concentration can be 16.5 M or less.
- the process after the etching is not particularly limited, and MXene particles can be obtained by a known method.
- the slurry after etching may be washed by repeating centrifugation-removal of supernatant liquid-addition of pure water to the remaining precipitate-centrifugation again, and then performing intercalation treatment and delamination treatment. ..
- the above-mentioned steps (c) to (f) may be carried out by the second manufacturing method.
- a virus inactivating liquid agent having a total content of chlorine and bromine in MXene particles of 1500 mass ppm or less can be produced.
- the Li content in the MXene particles can be reduced to 20% by mass or less.
- Each content of chlorine and bromine in MXene particles can be measured by combustion-ion chromatography.
- ultrasonic treatment is not performed as delamination after etching. Since no ultrasonic treatment is performed, particle destruction is unlikely to occur, and MXene particles containing a single-layer / small-layer MXene having a large two-dimensional surface can be obtained.
- MXene particles may carry at least one of a metal and a metal oxide. This makes it possible to improve the virus inactivating ability and / or add other functions (antibacterial property, catalytic function, etc.) depending on the metal and / or metal oxide to be carried.
- the metal constituting the metal or the metal oxide may be, for example, Ag.
- the MXene particles may carry the metal particles.
- MXene particles carry a metal oxide
- the metal (M) constituting the MXene layer is partially oxidized to the MXene particles (the above-mentioned partial oxidation).
- a metal oxide (generated by) may be carried.
- MXene particles carry metals and / or metal oxides means that in the XRD profile obtained by subjecting the particles to X-ray diffraction (XRD) measurements, MXene-specific peaks and metals and / or metals. It can be confirmed by detecting the peak peculiar to the oxide.
- XRD X-ray diffraction
- the detection of peaks specific to metals and / or metal oxides in the XRD profile is due to the content of the metal and / or metal oxides (overall standard for metal and / or metal oxide-bearing MXene particles). It means that it is mass% or more.
- MXene particles may carry titanium oxide. By supporting titanium oxide on the MXene particles, it becomes possible to add antibacterial properties to the virus inactivating liquid agent.
- the MXene particles may be supported by titanium oxide particles, or the Ti constituting the MXene layer may be partially oxidized to cause the MXene particles to be supported by titanium oxide (produced by the above partial oxidation). ..
- the present embodiment is not limited, but specifically, the above partial oxidation is carried out in the presence of oxygen, for example, at 60 to 80 ° C. (typically about 70 ° C.) for 50 to 250 hours (representative). It can be carried out by heating for 70 to 200 hours).
- Titanium oxide is not particularly limited, but may be anatase type.
- the MXene particles are Ti 3 C 2 T s
- the Ti contained therein is partially oxidized to generate TIO 2
- the TIO 2 -supported Ti 3 C 2 T s particles are obtained by X-ray diffraction of the particles.
- partial oxidation in MXene particles progresses excessively, it is not desirable from the viewpoint of dispersion stability, but as described above, even if partial oxidation occurs to some extent, the effect of virus inactivation is not significantly inactivated.
- partial oxidation may be appropriately promoted to achieve both the virus inactivating effect and the antibacterial property.
- the virus inactivated article 20 of the present embodiment is Base material 11 and It includes a virus inactivating layer 13 arranged on a substrate 11, and the virus inactivating layer 13 contains particles 10 of a predetermined layered material (MXene).
- MXene a predetermined layered material
- the substrate 11 can be any suitable article that may be desired to be imparted with a virus inactivating function.
- the substrate 11 can also be understood as a support that supports the virus inactivated layer 13.
- the material and form of the base material 11 are not particularly limited.
- the base material 11 may be composed of fibers, glass, a polymer / polymer composition (resin, plastic, etc.), ceramics, metals, and the like.
- the substrate 11 is selected from the group consisting of filters, masks, face shields, bandages, gloves, gowns, touch panels, displays (including monitors), films (including protective films) and stickers.
- the filter may be a filter used in an air purifier or an air conditioner, a filter (Membrane) used in a water purifier or a wastewater treatment facility, or the like.
- Masks, face shields, bandages, gloves, gowns, touch panels, displays, films and stickers can be common. Among them, masks, face shields, bandages, gloves, gowns, touch panels, and displays can be medical ones (those used in the medical field), and are particularly preferably used when they are easily exposed to a virus.
- Films and seals may have an adhesive layer on the opposite side of the surface on which the virus inactivated layer is placed, through which any other article or other (eg, touch panel, display, numerous humans can touch). It may be possible to attach it to a place where there is a possibility.
- the film may not have an adhesive layer and may be, for example, a porous film.
- the virus inactivating layer 13 can be formed by using the virus inactivating liquid agent described above in the first embodiment. More specifically, the virus inactivated article 20 of the present embodiment is (A) A virus inactivating liquid agent is applied onto the substrate 11 to form a precursor of a virus inactivating layer containing MXene particles, and (b) the precursor is dried (in other words,). , At least partially removed) to form the virus inactivated layer 13.
- the method of applying the virus inactivating liquid agent on the base material 11 is not particularly limited, and for example, spraying, spin casting, blade method, printing, brush coating, dipping and the like can be used.
- the above (a) and (b) may be repeated twice or more in total until the desired virus inactivated layer thickness is obtained.
- the virus inactivating layer 13 may be composed substantially only of MXene particles 10 (and optionally residual liquid medium), but in addition to MXene particles 10 (and optionally residual liquid medium), a dispersant. , Binders, antioxidants, viscosity modifiers and fragrances may further contain at least one additive (not shown) selected from the group.
- the MXene particles 10 are oriented as parallel as possible to the substrate surface 11a (flat). It is preferable, but not limited to, to form the virus inactivated layer 13 by being present in the state of). For example, when the surface of the substrate is not flat (the surface roughness is large), the MXene particles 10 may exist in a state of being oriented along the state of the surface of the substrate to form the virus inactivated layer 13. ..
- the surface 11a of the base material 11 is coated with the virus inactivated layer 13.
- the virus inactivated layer 13 may be coated on the entire surface of the substrate surface 11a or may be coated on a part of the substrate surface 11a.
- the thickness of the virus inactivated layer 13 may vary depending on the use of the virus inactivated article 20, and may be, for example, 0.1 ⁇ m or more and 1 mm or less.
- MXene particles can inactivate the virus by the same mechanism as described above in the first embodiment, and the effect of virus inactivation can be sustained for a long period of time. It can be demonstrated.
- Example 1 relates to one example of the virus inactivated liquid agent described above in Embodiment 1.
- Example 1 preparation of precursor (MAX), (2) etching of precursor, (3) cleaning, (4) delamination and (5) concentration adjustment are performed in order. This was carried out to prepare a virus inactivating liquid.
- precursor (MAX) TiC powder, Ti powder and Al powder (all manufactured by High Purity Chemical Laboratory Co., Ltd.) are put into a ball mill containing zirconia balls at a molar ratio of 2: 1: 1. And mixed for 24 hours. The obtained mixed powder was calcined at 1350 ° C. for 2 hours in an Ar atmosphere. The fired body (block) thus obtained was crushed with an end mill to a maximum size of 40 ⁇ m or less. As a result, Ti 3 AlC 2 particles were obtained as a precursor (MAX).
- the virus inactivating liquid agent of Example 1 was prepared, which contained single-layer / small-layer MXene (Ti 3C 2T s ) particles in pure water at 5 mg / mL.
- the pH of the liquid medium in this virus-inactivated liquid agent was 4.3. In this virus inactivating liquid agent, it was visually confirmed that the particles were well dispersed without agglomeration / sedimentation.
- Example 2 [Evaluation: Inactivation against enveloped virus] Using the virus inactivating liquid agent obtained in Example 1 as a sample (sample), an inactivation test for the enveloped virus of this sample was performed to evaluate the virus inactivating ability. Influenza virus was used as the envelope virus. The details of the test are as follows.
- Viruses used in the test Test virus Influenza A virus (H1N1) A / PR / 8/34 ATCC VR-1469 Cells used: MDCK (NBL-2) cell JCRB 9029 strain Medium used: -Cell proliferation medium Eagle MEM medium "Nissui” (1) (Nissui Pharmaceutical Co., Ltd.) supplemented with 10% fetal bovine serum was used. -Cell maintenance medium The following composition was used. Eagle MEM medium "Nissui” (1) 100 mL 10% sodium bicarbonate 14mL L-Glutamine (30g / L) 9.8mL Vitamin solution for MEM (100x) 30mL 10% albumin 20mL 0.25% Trypsin 20mL
- the virus infectivity titer can be measured without being affected by the sample by diluting the action solution 1000 times with the cell maintenance medium.
- the same test was performed using purified water as a control, and the virus infectivity titer was measured at the start (immediately after the start) and 1 minute, 5 minutes, 15 minutes, and 24 hours after the start.
- TCID 50 50% tissue culture infection amount
- the virus inactivating liquid agent (sample) of Example 1 had a virus infectivity value below the lower limit of detection within only 1 minute from the start of action, and could inactivate the virus in a short time. Was done. Furthermore, it was confirmed that the virus inactivating liquid agent (sample) of Example 1 had a virus infectivity value below the lower limit of detection even 24 hours after the start of action, and could sustainably inactivate the virus. Such a result showed that the virus inactivating liquid agent of Example 1 had a high virus inactivating ability against enveloped virus.
- the virus inactivating liquid agent of Example 1 is considered to have a high virus inactivating ability against non-enveloped viruses.
- Example 2 relates to a modified example of Example 1.
- Example 2 Preparation of virus inactivated liquid agent
- partial oxidation is carried out as an additional step, and then (5') concentration adjustment is carried out to inactivate the virus.
- a liquid agent was prepared.
- Example 2 First, the same operations as (1) preparation of the precursor (MAX), (2) etching of the precursor, (3) cleaning, and (4) delamination described in detail in Example 1 are carried out. A layer / small layer MXene (Ti 3 C 2 T s ) particle-containing liquid was obtained.
- the monolayer / small layer MXene (Ti 3C 2T s ) particle-containing liquid thus obtained had a solid particle concentration of 125 mg / mL.
- the single-layer / small-layer MXene (Ti 3 C 2 Ts) particle-containing liquid (before treatment) and the treatment liquid (after treatment) ) The solid content (particles) was collected and observed with a scanning electron microscope (SEM). The obtained SEM photograph is shown in FIG. Compared with the state before the treatment shown in FIG . 3 (a), in the state after the treatment shown in FIG. Observed) was observed. Further, the solid content (particles) was subjected to X-ray diffraction (XRD) measurement to obtain an XRD profile.
- XRD X-ray diffraction
- a virus-inactivated liquid agent of Example 2 was prepared, which contained single-layer / small-layer MXene (Ti 3 C 2 T s ) particles carrying TiO 2 in pure water at 5 mg / mL.
- the pH of the liquid medium in this virus-inactivated liquid agent was 4.3. In this virus inactivating liquid agent, it was visually confirmed that the particles were well dispersed without agglomeration / sedimentation.
- Example 2 [Evaluation: Inactivation against enveloped virus] Using the virus inactivating liquid agent obtained in Example 2 as a sample (sample), an inactivation test for the enveloped virus of this sample was carried out in the same manner as in Example 1 to evaluate the virus inactivating ability. The results obtained thereby showed that the virus inactivating liquid agent of Example 2 had a high virus inactivating ability against enveloped viruses.
- the virus inactivating liquid agent of Example 2 is considered to have a high virus inactivating ability against non-enveloped viruses.
- Example 3 relates to the virus inactivated article described above in the second embodiment.
- Example 3 [Manufacturing of virus inactivated products]
- a virus inactivating liquid agent was applied onto the substrate to form a virus inactivating layer, whereby the virus inactivating layer was arranged on the substrate.
- Manufactured virus inactivated articles Manufactured virus inactivated articles.
- Example 2 the same operation as in Example 1 was carried out except that the dilution with pure water was changed by adjusting the concentration in (5) above, and the single-layer / small-layer MXene (Ti 3 C 2 T s ) particles were carried out.
- the average value of the thickness of the MXene particles was 1 nm or more and 10 nm or less, and the average size of the MXene particles in the two-dimensional sheet surface was 3 ⁇ m.
- This virus inactivating liquid agent is a dispersion liquid in which MXene (Ti 3C 2T s ) particles are dispersed in pure water, and does not contain additives such as binders and dispersants.
- a glass substrate whose surface was hydrophilized by UV treatment was prepared as a base material.
- the operation of spraying the virus inactivating liquid agent prepared above on the hydrophilic surface of the glass substrate and then blowing warm air with a desiccant is repeated 30 times, and then further, in a normal pressure oven at 80 ° C. After pre-drying for 2 hours and main drying at 150 ° C. for 18 hours in a vacuum oven (drying substantially removed pure water as a liquid medium).
- a virus inactivated layer composed of single-layer / small-layer MXene (Ti 3C 2T s ) particles was formed on the hydrophilic surface of the glass substrate.
- the thickness of the virus inactivated layer was about 2 ⁇ m.
- Example 3 As described above, the virus inactivated article of Example 3 in which the virus inactivated layer composed of single-layer / small-layer MXene (Ti 3 C 2 T s ) particles was arranged on a glass substrate was obtained.
- the virus inactivating article of Example 3 is considered to have a high virus inactivating ability against enveloped viruses.
- the virus inactivating article of Example 3 is considered to have a high virus inactivating ability against non-enveloped viruses.
- Example 4 relates to another example of the virus inactivated liquid agent described above in Embodiment 1.
- Example 4 (1) preparation of precursor (MAX), (2) etching of precursor, (3) cleaning after etching, (4) intercalation of Li, and (5) described in detail below. Delamination was carried out in order to prepare a virus inactivating liquid agent.
- the supernatant was centrifuged at 4300 G for 2 hours using a centrifuge, and then the supernatant was discarded to obtain a single-layer / small-layer MXene-containing clay. 1 mg of the clay thus obtained was taken and redistributed in 10 mL of pure water.
- a virus-inactivated liquid agent of Example 4 was prepared, which contained single-layer / small-layer MXene (Ti 3 C 2 T s ) particles in pure water at about 3 mg / mL.
- the pH of the liquid medium in this virus-inactivated liquid agent was 2.7. In this virus inactivating liquid agent, it was visually confirmed that the particles were well dispersed without agglomeration / sedimentation.
- Example 5 relates to a modified example of Example 4.
- Example 5 a virus inactivating liquid agent was prepared in the same manner as in Example 4 except that the charged composition under the conditions of Li intercalation was as follows in the above (4) Li intercalation. did. ⁇ Preparation composition: MXene (Ti 3 C 2 T s ) Particle-Moisture Medium Clay: Solid Content 0.75 g LiCl 0.97g LiOH + H 2 O about 0.03g Pure water 20.00g
- Example 5 a virus-inactivated liquid agent of Example 5 containing single-layer / small-layer MXene (Ti 3 C 2 T s ) particles in pure water at about 2 mg / mL was prepared.
- the pH of the liquid medium in this virus-inactivated liquid agent was 6.9.
- Example 6 relates to yet another example of the virus inactivating liquid agent described above in the first embodiment.
- Example 6 in the above-mentioned (4) Li intercalation, the charged composition under the conditions of the Li intercalation was set as follows, and instead of the above-mentioned (5) delamination, the following (5') de-decalation was performed. Except for the fact that lamination was performed, the same procedure as in Example 4 was carried out, and then (6) acid treatment and (7) water washing were carried out in order to prepare a virus inactivating liquid agent. (Conditions for Li intercalation) ⁇ Preparation composition: MXene (Ti 3 C 2 T s ) Particle-Moisture Medium Clay: Solid Content 0.75 g LiCl 0.75g
- Example 6 a virus-inactivated liquid agent of Example 6 containing single-layer / small-layer MXene (Ti 3 C 2 T s ) particles in pure water at about 3 mg / mL was prepared.
- the pH of the liquid medium in this virus-inactivated liquid agent was 4.3.
- this virus inactivating liquid agent it was visually confirmed that the particles were well dispersed without agglomeration / sedimentation.
- MXene was liquefied by an alkaline melting method, and the Li content was measured by ICP-AES (using iCAP7400 manufactured by Thermo Fisher Scientific Co., Ltd.) using inductively coupled plasma emission spectroscopy. As a result, the Li content was 4 mass ppm.
- Example 7 relates to yet another example of the virus inactivated liquid agent described above in Embodiment 1.
- Example 7 (1) preparation of precursor (MAX), (2) etching of precursor, (3) cleaning after etching, (4) intercalation of Li, and (5) described in detail below. Delamination was carried out in order to prepare a virus inactivating liquid agent.
- a virus-inactivated liquid agent of Example 7 was prepared, which contained single-layer / small-layer MXene (Ti 3 C 2 T s ) particles in pure water at about 3 mg / mL.
- the pH of the liquid medium in this virus-inactivated liquid agent was 4.3. In this virus inactivating liquid agent, it was visually confirmed that the particles were well dispersed without agglomeration / sedimentation.
- virus inactivating liquid agent and the virus inactivating article of the present disclosure can inactivate the virus, they can be used to prevent humans and other organisms from being infected with the virus.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Health & Medical Sciences (AREA)
- Dentistry (AREA)
- Pest Control & Pesticides (AREA)
- Plant Pathology (AREA)
- Engineering & Computer Science (AREA)
- Agronomy & Crop Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Toxicology (AREA)
- Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
Description
前記層が、以下の式:
MmXn
(式中、Mは、少なくとも1種の第3、4、5、6、7族金属であり、
Xは、炭素原子、窒素原子またはそれらの組み合わせであり、
nは、1以上4以下であり、
mは、nより大きく、5以下である)
で表される層本体と、該層本体の表面に存在する修飾または終端T(Tは、水酸基、フッ素原子、塩素原子および酸素原子からなる群より選択される少なくとも1種である)とを含む、ウイルス不活化液状剤が提供される。
基材と、
前記基材上に配置されたウイルス不活化層と
を含み、前記ウイルス不活化層が、1つまたは複数の層を含む層状材料の粒子を含み、
前記層が、以下の式:
MmXn
(式中、Mは、少なくとも1種の第3、4、5、6、7族金属であり、
Xは、炭素原子、窒素原子またはそれらの組み合わせであり、
nは、1以上4以下であり、
mは、nより大きく、5以下である)
で表される層本体と、該層本体の表面に存在する修飾または終端T(Tは、水酸基、フッ素原子、塩素原子および酸素原子からなる群より選択される少なくとも1種である)とを含む、ウイルス不活化物品が提供される。
以下、本開示の1つの実施形態におけるウイルス不活化液状剤について詳述するが、本開示はかかる実施形態に限定されるものではない。
1つまたは複数の層を含む層状材料であって、該層が、以下の式:
MmXn
(式中、Mは、少なくとも1種の第3、4、5、6、7族金属であり、いわゆる早期遷移金属、例えばSc、Ti、Zr、Hf、V、Nb、Ta、Cr、MoおよびMnからなる群より選択される少なくとも1種を含み得、
Xは、炭素原子、窒素原子またはそれらの組み合わせであり、
nは、1以上4以下であり、
mは、nより大きく、5以下である)
で表される層本体(該層本体は、各XがMの八面体アレイ内に位置する結晶格子を有し得る)と、該層本体の表面(より詳細には、該層本体の互いに対向する2つの表面の少なくとも一方)に存在する修飾または終端T(Tは、水酸基、フッ素原子、塩素原子および酸素原子からなる群より選択される少なくとも1種である)とを含む層状材料(これは層状化合物として理解され得、「MmXnTs」とも表され、sは任意の数であり、従来、sに代えてxが使用されることもある)。代表的には、nは、1、2、3または4であり得るが、これに限定されない。
Sc2C、Ti2C、Ti2N、Zr2C、Zr2N、Hf2C、Hf2N、V2C、V2N、Nb2C、Ta2C、Cr2C、Cr2N、Mo2C、Mo1.3C、Cr1.3C、(Ti,V)2C、(Ti,Nb)2C、W2C、W1.3C、Mo2N、Nb1.3C、Mo1.3Y0.6C(上記式中、「1.3」および「0.6」は、それぞれ約1.3(=4/3)および約0.6(=2/3)を意味する。)、
Ti3C2、Ti3N2、Ti3(CN)、Zr3C2、(Ti,V)3C2、(Ti2Nb)C2、(Ti2Ta)C2、(Ti2Mn)C2、Hf3C2、(Hf2V)C2、(Hf2Mn)C2、(V2Ti)C2、(Cr2Ti)C2、(Cr2V)C2、(Cr2Nb)C2、(Cr2Ta)C2、(Mo2Sc)C2、(Mo2Ti)C2、(Mo2Zr)C2、(Mo2Hf)C2、(Mo2V)C2、(Mo2Nb)C2、(Mo2Ta)C2、(W2Ti)C2、(W2Zr)C2、(W2Hf)C2、
Ti4N3、V4C3、Nb4C3、Ta4C3、(Ti,Nb)4C3、(Nb,Zr)4C3、(Ti2Nb2)C3、(Ti2Ta2)C3、(V2Ti2)C3、(V2Nb2)C3、(V2Ta2)C3、(Nb2Ta2)C3、(Cr2Ti2)C3、(Cr2V2)C3、(Cr2Nb2)C3、(Cr2Ta2)C3、(Mo2Ti2)C3、(Mo2Zr2)C3、(Mo2Hf2)C3、(Mo2V2)C3、(Mo2Nb2)C3、(Mo2Ta2)C3、(W2Ti2)C3、(W2Zr2)C3、(W2Hf2)C3
MmAXn
(式中、M、X、nおよびmは、上記の通りであり、Aは、少なくとも1種の第12、13、14、15、16族元素であり、通常はA族元素、代表的にはIIIA族およびIVA族であり、より詳細にはAl、Ga、In、Tl、Si、Ge、Sn、Pb、P、As、SおよびCdからなる群より選択される少なくとも1種を含み得、好ましくはAlである)
で表され、かつ、MmXnで表される2つの層(各XがMの八面体アレイ内に位置する結晶格子を有し得る)の間に、A原子により構成される層が位置した結晶構造を有する。MAX相は、代表的にm=n+1の場合、n+1層のM原子の層の各間にX原子の層が1層ずつ配置され(これらを合わせて「MmXn層」とも称する)、n+1番目のM原子の層の次の層としてA原子の層(「A原子層」)が配置された繰り返し単位を有するが、これに限定されない。MAX相からA原子(および場合によりM原子の一部)が選択的にエッチング(除去および場合により層分離)されることにより、A原子層(および場合によりM原子の一部)が除去されて、露出したMmXn層の表面にエッチング液(通常、含フッ素酸の水溶液が使用されるがこれに限定されない)中に存在する水酸基、フッ素原子、塩素原子および酸素原子等が修飾して、かかる表面を終端する。
(a)MAX相から構成される前駆体を準備すること、
(b1)エッチング液を用いて、前記前駆体から少なくとも一部のA原子を除去する、エッチング処理を行うこと、
(c)前記エッチング処理により得られたエッチング処理物と、Li含有化合物とを混合して撹拌する工程を含む、Liインターカレーション処理を行うこと、
(d)前記Liインターカレーション処理して得られたLiインターカレーション処理物を、遠心分離し、上澄み液を廃棄後に残りの沈殿物を水で洗浄する工程を含む、デラミネーション処理を行うこと、
(e)前記デラミネーション処理して得られたデラミネーション処理物と、酸溶液を混合して撹拌する工程を含む、酸処理を行うこと、
(f)酸処理して得られた酸処理物を、水で洗浄してMXene粒子を得ること、および
(g)得られたMXene粒子を液状媒体と混合して、ウイルス不活化液状剤を得ること
を含む。この製造方法により、MXene粒子中のLi含有率が0.0020質量%(20質量ppm)以下である、ウイルス不活化液状剤を製造できる。
(a)MAX相から構成される前駆体を準備すること、
(b2)Li含有化合物を含むエッチング液を用いて、前記前駆体から少なくとも一部のA原子をエッチングするとともに、Liインターカレーション処理を行うこと、
(d)前記エッチングおよびLiインターカレーション処理して得られた(エッチング+Liインターカレーション)処理物を、遠心分離し、上澄み液を廃棄後に残りの沈殿物を水で洗浄する工程を含む、デラミネーション処理を行うこと、
(e)前記デラミネーション処理して得られたデラミネーション処理物と、酸溶液を混合して撹拌する工程を含む、酸処理を行うこと、
(f)酸処理して得られた酸処理物を、水で洗浄してMXene粒子を得ること、および
(g)得られたMXene粒子を液状媒体と混合して、ウイルス不活化液状剤を得ること
を含む。この製造方法により、MXene粒子中のLi含有率が0.0020質量%(20質量ppm)以下である、ウイルス不活化液状剤を製造できる。
以下、第1製造方法と第2製造方法の各工程について詳述する。これら2つの製造方法で共通する工程(a)と工程(d)~(g)はまとめて説明する。
まず、MAX相から構成される前駆体を準備する。MAX相は上述の通りである。前駆体は、MAX相に加えて、不可避的に混入する微量の不純物を含んでいてもよい。
第1製造方法では、エッチング液を用いて、前記前駆体から少なくとも一部のA原子を除去する、エッチング処理を行う。エッチング処理の条件は、特に限定されず、既知の条件を採用することができる。エッチングは、F-を含むエッチング液を用いて実施され得、例えば、フッ酸を用いた方法、フッ化リチウムおよび塩酸の混合液を用いた方法、これらに更にリン酸等を含むエッチング液を用いた方法が挙げられる。これらの方法では、溶媒として例えば純水との混合液を用いた方法が挙げられる。上記エッチング処理により得られたエッチング処理物として例えばスラリーが挙げられる。
前記エッチング処理により得られたエッチング処理物と、Li含有化合物とを混合して撹拌する工程を含む、Liインターカレーション処理を行う。
第2製造方法では、Li含有化合物を含むエッチング液を用いて、前記前駆体から、少なくとも一部のA原子(および場合によりM原子の一部)をエッチング(除去および場合により層分離)するとともに、Liインターカレーション処理を行う。
第1製造方法におけるLiインターカレーション処理により得られたLiインターカレーション処理物、または第2製造方法におけるエッチングおよびLiインターカレーション処理により得られた(エッチング+Liインターカレーション)処理物を、遠心分離し、上澄み液を廃棄後に残りの沈殿物を水で洗浄する工程を含む、デラミネーション処理を行う。デラミネーション処理の条件は特に限定されず、既知の方法で行うことができる。例えば下記に示す方法で行うことが挙げられる。
前記デラミネーション処理して得られた、デラミネーション処理物(単層・少層MXene含有上澄み液または単層・少層MXene含有クレイ)と、酸溶液とを、混合して撹拌する工程を含む、酸処理を行う。上記酸処理に用いる酸は限定されず、例えば鉱酸等の無機酸、および/または有機酸を用いることができる。前記酸は、好ましくは無機酸のみ、または無機酸と有機酸の混合酸である。前記酸は、より好ましくは無機酸のみである。上記無機酸として例えば、塩酸、硫酸、硝酸、リン酸、過塩素酸、ヨウ化水素酸、臭化水素酸、フッ酸等のうちの1以上を用いることができる。好ましくは、塩酸、硫酸のうちの1以上である。上記有機酸として例えば、酢酸、クエン酸、シュウ酸、安息香酸、ソルビン酸などが挙げられる。デラミネーション処理物と混合させる酸溶液の濃度は、処理対象となるデラミネーション処理物の量や濃度等に応じて調整すればよい。
酸処理して得られた酸処理物を、水で洗浄してMXene粒子を得る。酸処理物と混合させる水の量や洗浄方法は特に限定されない。例えば水を加えて撹拌、遠心分離等を行うことが挙げられる。撹拌方法として、ハンドシェイク、オートマチックシェイカー、シェアミキサー、ポットミルなどを用いた撹拌が挙げられる。撹拌速度、撹拌時間等の撹拌の程度は、処理対象となる酸処理物の量や濃度等に応じて調整すればよい。前記水での洗浄は1回以上行えばよい。好ましくは水での洗浄を複数回行うことである。例えば具体的に、(i)(酸処理物または下記(iii)で得られた残りの沈殿物に)水を加えて撹拌、(ii)撹拌物を遠心分離する、(iii)遠心分離後に上澄み液を廃棄する、の工程(i)~(iii)を2回以上、例えば10回以下の範囲内で行うことが挙げられる。
上記のようにして得られたMXene粒子を液状媒体と混合して、ウイルス不活化液状剤が得られる。液状媒体の詳細は、上述の通りである。液状媒体が水である場合、工程(f)の洗浄で使用する水(水での洗浄を2回以上実施する場合は最終回で使用する水)は、工程(g)で使用する液状媒体を兼ねていてもよい。
(a)MAX相から構成される前駆体を準備すること、
(b3)エッチング液を用いて、前記前駆体からA原子をエッチングすることであって、前記エッチング液は、H3PO4濃度が5.5M以上、HI濃度が5.0M以上、およびH2SO4濃度が5.0M以上からなる群より選択される少なくとも1つを満たすこと、および
(g3)得られたMXene粒子を液状媒体と混合して、ウイルス不活化液状剤を得ること
を含む。
まず、MAX相から構成される前駆体を準備する。この工程は、第1製造方法および第2製造方法と同様である。
エッチング液を用いて、前記前駆体からA原子(および場合によりM原子の一部)をエッチング(除去および場合により層分離)する。前記エッチング液として、H3PO4濃度が5.5M以上、HI濃度が5.0M以上、およびH2SO4濃度が5.0M以上からなる群より選択される少なくとも1つを満たすエッチング液を用いる。
上記のようにして得られたMXene粒子を液状媒体と混合して、ウイルス不活化液状剤が得られる。液状媒体の詳細は、上述の通りである。工程(b3)の後、上述した工程(c)~(f)を実施する場合、工程(g3)は、上述した工程(g)と同様の説明が当て嵌まり得る。
以下、本開示の1つの実施形態におけるウイルス不活化物品について詳述するが、本開示はかかる実施形態に限定されるものではない。
基材11と、
基材11上に配置されたウイルス不活化層13と
を含み、ウイルス不活化層13が、所定の層状材料(MXene)の粒子10を含む。
(a)ウイルス不活化液状剤を基材11上に適用して、MXeneの粒子を含むウイルス不活化層の前駆体を形成すること、および
(b)上記前駆体を乾燥させて(換言すれば、液状媒体を少なくとも部分的に除去して)、ウイルス不活化層13を形成すること
によって製造され得る。
実施例1は、実施形態1にて上述したウイルス不活化液状剤の1つの例に関する。
実施例1では、以下に詳述するように、(1)前駆体(MAX)の準備、(2)前駆体のエッチング、(3)洗浄、(4)デラミネーションおよび(5)濃度調整を順に実施して、ウイルス不活化液状剤を調製した。
TiC粉末、Ti粉末およびAl粉末(いずれも株式会社高純度化学研究所製)を2:1:1のモル比で、ジルコニアボールを入れたボールミルに投入して24時間混合した。得られた混合粉末をAr雰囲気下にて1350℃で2時間焼成した。これにより得られた焼成体(ブロック)をエンドミルで最大寸法40μm以下まで粉砕した。これにより、前駆体(MAX)としてTi3AlC2粒子を得た。
上記方法で調製したTi3AlC2粒子(粉末)を用い、下記エッチング条件でエッチングを行って、Ti3AlC2粉末に由来する固体成分を含む固液混合物(スラリー)を得た。
(エッチング条件)
・前駆体:Ti3AlC2(目開き45μmふるい通し)
・エッチング液組成:LiF3gおよび塩酸(9モル/L)30mLの混合物
・前駆体投入量:3.0g
・エッチング容器:100mLアイボーイ
・エッチング温度:35℃
・エッチング時間:24h
・スターラー回転数:400rpm
上記スラリーを3分割して、50mL遠沈管3本にそれぞれ挿入し、遠心分離機を用いて相対遠心力(RCF)3500Gの条件で遠心分離を行った後(これによりクレイが沈降する)、上澄み液を分離除去(廃棄)した。各遠沈管(上澄み液が分離除去された残部が存在する)に純水40mLを追加し、再度3500Gで遠心分離を行って、上澄み液を分離除去するという操作を11回繰り返した。そして最終的に、上澄み液が分離除去された残部(沈殿物)として、MXene(Ti3C2Ts)粒子-水分媒体クレイを得た。
上記MXene(Ti3C2Ts)粒子-水分媒体クレイに純水40mLを追加してからシェーカーで15分間撹拌後に、3500Gで遠心分離し、上澄み液を、単層・少層MXene(Ti3C2Ts)粒子含有液として回収した。単層・少層MXene(Ti3C2Ts)粒子含有液に含まれるMXene粒子の厚さの平均値は、1nm以上10nm以下であった(以下の実施例も同様)。
上記単層・少層MXene(Ti3C2Ts)粒子含有液を純水で希釈して、固形分である粒子の濃度が5mg/mLとなるように調整して、ウイルス不活化液状剤を得た。
実施例1で得られたウイルス不活化液状剤を検体(試料)とし、この検体のエンベロープウイルスに対する不活化試験を行って、ウイルス不活化能を評価した。エンベロープウイルスにはインフルエンザウイルスを使用した。試験の詳細は下記の通り。
試験ウイルス:
Influenza A virus (H1N1) A/PR/8/34 ATCC VR-1469
使用細胞:
MDCK(NBL-2)細胞JCRB 9029株
使用培地:
・細胞増殖培地
イーグルMEM培地「ニッスイ」(1)(日水製薬株式会社)に牛胎仔血清を10%加えたものを使用した。
・細胞維持培地
下記組成のものを使用した。
イーグルMEM培地「ニッスイ」(1) 100mL
10%炭酸水素ナトリウム 14mL
L-グルタミン(30g/L) 9.8mL
MEM用ビタミン液(100x) 30mL
10%アルブミン 20mL
0.25%トリプシン 20mL
・細胞の培養
細胞培養用フラスコ内にて、細胞増殖培地を用いて、使用細胞を単層培養した。
・ウイルスの接種
単層培養後、上記フラスコ内から細胞増殖培地を除き、試験ウイルスを接種した。次に、細胞維持培地を加えて37℃±1℃の炭酸ガスインキュベーター(CO2濃度:5%)内で1~5日間培養した。
・ウイルス液の調製
上記培養後、倒立位相差顕微鏡を用いて細胞の形態を観察し、細胞に形態変化(細胞変性効果)が起こっていることを確認した。次に、培養液を遠心分離(3000rpm、10分間)し、上澄み液を分離回収した。得られた上澄み液を精製水で10倍希釈して、ウイルス液を得た。
検体(ウイルス不活化液状剤)1mLに、上記ウイルス液0.1mLを添加、混合して混合液(以下、「作用液」と言う)を得た。
作用液を室温にて維持することで作用させ、開始から1分、5分、15分、24時間後に、作用液を細胞維持培地で1000倍に希釈し、ウイルス感染価を測定した。(なお、予備試験において、作用液を細胞維持培地で1000倍に希釈することにより、検体の影響を受けずにウイルス感染価を測定できることを予め確認した。)
また、対照として精製水を用いて同様に試験し、開始時(開始直後)および開始から1分、5分、15分、24時間後に、ウイルス感染価を測定した。
組織培養用マイクロプレート(96穴)内にて、細胞増殖培地を用いて、使用細胞を単層培養した後、細胞増殖培地を除き、細胞維持培地を(各穴に)0.1mLずつ加えた。次に、上記100倍希釈後の作用液および上記対照を、細胞維持培地を用いて10倍ずつ段階的に希釈した。得られた希釈液0.1mLを、各希釈倍率につき4穴ずつに接種し、37℃±1℃の炭酸ガスインキュベーター(CO2濃度:5%)内で4~7日間培養した。
上記培養後、倒立位相差顕微鏡を用いて細胞の形態変化(細胞変性効果)の有無を観察し、Reed-Muench法により50%組織培養感染量(TCID50)を算出して、作用液1mL当たりのウイルス感染価(log10TCID50/mL)に換算した。
ウイルス感染価(log10TCID50/mL)の測定結果を表1に示す。
実施例1のウイルス不活化液状剤は、ノンエンベロープウイルスに対しても高いウイルス不活化能を有するものと考えられる。
実施例2は、実施例1の改変例に関する。
実施例2では、以下に詳述するように、実施例1の(4)デラミネーションの後に、追加工程として部分酸化を実施し、その後、(5’)濃度調整を実施して、ウイルス不活化液状剤を調製した。
上記単層・少層MXene(Ti3C2Ts)粒子含有液を、酸素を含む相対湿度90%の環境下にて70℃の加熱処理(酸化処理)に付して、処理液を得た。処理時間は194.5時間とした。
上記加熱処理(酸化処理)後の処理液を純水で希釈して、固形分である粒子の濃度が5mg/mLとなるように調整して、ウイルス不活化液状剤を得た。
実施例2で得られたウイルス不活化液状剤を検体(試料)とし、この検体のエンベロープウイルスに対する不活化試験を、実施例1と同様にして行って、ウイルス不活化能を評価した。これにより得られた結果は、実施例2のウイルス不活化液状剤が、エンベロープウイルスに対して高いウイルス不活化能を有することを示すものであった。
実施例2のウイルス不活化液状剤は、ノンエンベロープウイルスに対しても高いウイルス不活化能を有するものと考えられる。
実施例3は、実施形態2にて上述したウイルス不活化物品に関する。
実施例3では、以下に詳述するように、ウイルス不活化液状剤を基材上に適用して、ウイルス不活化層を形成し、これにより、基材上にウイルス不活化層が配置されたウイルス不活化物品を製造した。
このウイルス不活化液状剤において、MXene粒子の厚さの平均値は、1nm以上10nm以下であり、MXene粒子の二次元シート面内における平均寸法は、3μmであった。
このウイルス不活化液状剤は、MXene(Ti3C2Ts)粒子が純水中に分散した分散液であり、バインダや分散剤などの添加剤を含まないものとした。
実施例3のウイルス不活化物品は、エンベロープウイルスに対して高いウイルス不活化能を有するものと考えられる。
実施例3のウイルス不活化物品は、ノンエンベロープウイルスに対しても高いウイルス不活化能を有するものと考えられる。
実施例4は、実施形態1にて上述したウイルス不活化液状剤のもう1つの例に関する。
実施例1と同様にして、前駆体(粉末状MAX)としてTi3AlC2粒子を得た。
エッチング条件におけるエッチング液組成を下記としたこと以外は、実施例1と同様にして、Ti3AlC2粉末に由来する固体成分を含む固液混合物(スラリー)を得た。
・エッチング液組成:49%HF 6mL
H2O 18mL
HCl(12M) 36mL
上記スラリーを2分割して、50mL遠沈管2本にそれぞれ挿入したこと以外は、実施例1と同様にして、MXene(Ti3C2Ts)粒子-水分媒体クレイを得た。
上記方法で調製したMXene(Ti3C2Ts)粒子-水分媒体クレイに対し、下記条件の通り、所定温度範囲で所定時間撹拌して、Liのインターカレーションを行った。
(Liのインターカレーションの条件)
・仕込み組成:
MXene(Ti3C2Ts)粒子-水分媒体クレイ:固形分0.75g
LiCl 1.00g
HCl 約0.67g
純水 19.42g
・インターカレーション容器:100mLアイボーイ
・温度:20℃以上25℃以下(室温)
・時間:12h
・スターラー回転数:800rpm
Liのインターカレーションを行って得られたスラリーを、50mL遠沈管に投入し、遠心分離機を用いて3500Gの条件で遠心分離を行った後、上澄み液を廃棄した。次いで、(i)残りの沈殿物に純水40mLを追加してからシェーカーで15分間撹拌後に、(ii)3500Gで遠心分離し、(iii)上澄み液を単層・少層MXene含有液として回収した。この(i)~(iii)の操作を、合計4回繰り返して、単層・少層MXene含有上澄み液を得た。さらに、この上澄み液を、遠心分離機を用いて4300G、2時間の条件で遠心分離を行った後、上澄み液を廃棄し、単層・少層MXene含有クレイを得た。これにより得られたクレイを1mgとり、10mLの純水に再分散させた。
実施例2は、実施例4の改変例に関する。
・仕込み組成:
MXene(Ti3C2Ts)粒子-水分媒体クレイ:固形分0.75g
LiCl 0.97g
LiOH+H2O 約0.03g
純水 20.00g
実施例6は、実施形態1にて上述したウイルス不活化液状剤の更にもう1つの例に関する。
(Liのインターカレーションの条件)
・仕込み組成:
MXene(Ti3C2Ts)粒子-水分媒体クレイ:固形分0.75g
LiCl 0.75g
Liのインターカレーションを行って得られたスラリーを、50mL遠沈管に投入し、遠心分離機を用いて3500Gの条件で遠心分離を行った後、上澄み液を廃棄した。次いで、(i)残りの沈殿物に純水40mLを追加してからシェーカーで15分間撹拌後に、(ii)3500Gで遠心分離し、(iii)上澄み液を単層・少層MXene含有液として回収した。この(i)~(iii)の操作を、合計4回繰り返して、単層・少層MXene含有上澄み液を得た。さらに、この上澄み液を、遠心分離機を用いて4300G、2時間の条件で遠心分離を行った後、上澄み液を廃棄し、単層・少層MXene含有クレイを得た。
上記の単層・少層MXene含有クレイに、(i)1.8Mの塩酸を35mL追加してからシェーカーで5分間撹拌後に、(ii)3500Gで遠心分離を行い、(iii)上澄み液を廃棄した。この(i)~(iii)の操作を合計5回繰り返した。
上記酸処理後の単層・少層MXene含有クレイに、(i)水を35mL追加してからシェーカーで5分間撹拌後に、(ii)3500Gで遠心分離を行い、(iii)上澄み液を廃棄した。この(i)~(iii)の操作を合計5回繰り返して、単層・少層MXene含有試料として単層・少層MXene含有クレイを得た。上記上澄み液は最終的にpHが4以上になっていることを確認した。これにより得られたクレイを1mgとり、10mLの純水に再分散させた。
MXeneをアルカリ溶融法により溶液化し、誘導結合プラズマ発光分光分析法を用いたICP-AES(サーモフィッシャーサイエンティフィック社製のiCAP7400を使用)でLi含有率を測定した。その結果、Li含有率は4質量ppmであった。
実施例7は、実施形態1にて上述したウイルス不活化液状剤の更にもう1つの例に関する。
実施例1と同様にして、前駆体(粉末状MAX)としてTi3AlC2粒子を得た。
エッチング条件におけるエッチング液組成を下記としたこと以外は、実施例1と同様にして、Ti3AlC2粉末に由来する固体成分を含む固液混合物(スラリー)を得た。
(エッチング条件)
・エッチング液組成:HF濃度 2.8M
H3PO4濃度 7.4M
上記スラリーを2分割して、50mL遠沈管2本にそれぞれ挿入したこと以外は、実施例1と同様にして、MXene(Ti3C2Ts)粒子-水分媒体クレイを得た。
上記方法で調製したMXene(Ti3C2Ts)粒子-水分媒体クレイに対し、Li3PO4、H3PO4および純水を加え、所定温度範囲で所定時間撹拌して、Liのインターカレーションを行った。
(Liインターカレーションの条件)
・仕込み組成:
MXene(Ti3C2Ts)粒子-水分媒体クレイ:固形分0.75g
Li3PO4:0.68g
85質量%H3PO4:3.1mL
純水:31.9mL
・インターカレーション容器:100mLアイボーイ
・温度:20℃以上25℃以下(室温)
・時間:15h
・スターラー回転数:800rpm
Liのインターカレーションを行って得られたスラリーを、50mL遠沈管に投入し、遠心分離機を用いて3500Gの条件で遠心分離を行った後、上澄み液を廃棄した。次いで、上澄みを除いた残りの沈殿物に純水40mLを追加してからシェーカーで15分間撹拌後に、3500Gで遠心分離し、上澄み液を、単層・少層MXene含有液として回収する操作を、4回繰り返して、単層・少層MXene含有液状物を得た。
実施例7で得られたMXene粒子中の塩素含有率と臭素含有率を、サーモフィッシャーサイエンティフィック社製の燃焼-イオンクロマトグラフィー装置(Dionex ICS-5000)を用いて測定した。その結果、塩素含有率は50質量ppm以下であり、臭素含有率も50質量ppm以下、すなわち、塩素と臭素の合計含有率は100質量ppm以下であった。
実施例4~7のウイルス不活化液状剤は、実施例1のウイルス不活化液状剤と同様に、エンベロープウイルスおよびノンエンベロープウイルスに対して高いウイルス不活化能を有するものと考えられる。
3a、5a、3b、5b 修飾または終端T
7a、7b MXene層
10、10a、10b MXene(層状材料)粒子
11 基材
11a 基材表面
13 ウイルス不活化層
20 ウイルス不活化物品
Claims (20)
- ウイルス不活化液状剤であって、液状媒体と、1つまたは複数の層を含む層状材料の粒子とを含み、
前記層が、以下の式:
MmXn
(式中、Mは、少なくとも1種の第3、4、5、6、7族金属であり、
Xは、炭素原子、窒素原子またはそれらの組み合わせであり、
nは、1以上4以下であり、
mは、nより大きく、5以下である)
で表される層本体と、該層本体の表面に存在する修飾または終端T(Tは、水酸基、フッ素原子、塩素原子および酸素原子からなる群より選択される少なくとも1種である)とを含む、ウイルス不活化液状剤。 - 前記MmXnが、Ti3C2である、請求項1に記載のウイルス不活化液状剤。
- 前記粒子の厚さの平均値が、10nm以下である、請求項1または2に記載のウイルス不活化液状剤。
- 前記液状媒体が、水およびアルコールの少なくとも一方を含む、請求項1~3のいずれかに記載のウイルス不活化液状剤。
- 分散剤、バインダ、酸化防止剤、粘度調整剤および香料からなる群より選択される少なくとも1つの添加剤を更に含む、請求項1~4のいずれかに記載のウイルス不活化液状剤。
- 前記ウイルス不活化液状剤における前記粒子の含有量が、0.5mg/mL以上100mg/mL以下である、請求項1~5のいずれかに記載のウイルス不活化液状剤。
- 前記液状媒体のpHが、2.7以上7.0以下である、請求項1~6のいずれかに記載のウイルス不活化液状剤。
- 前記粒子におけるLiの含有率が、20質量ppm以下である、請求項1~7のいずれかに記載のウイルス不活化液状剤。
- 前記粒子における塩素と臭素の合計含有率が、1500質量ppm以下である、請求項1~8のいずれかに記載のウイルス不活化液状剤。
- 前記粒子が、金属および金属酸化物の少なくとも一方を担持している、請求項1~9のいずれかに記載のウイルス不活化液状剤。
- 前記粒子が、酸化チタンを担持している、請求項1~10のいずれかに記載のウイルス不活化液状剤。
- ウイルス不活化物品であって、
基材と、
前記基材上に配置されたウイルス不活化層と
を含み、前記ウイルス不活化層が、1つまたは複数の層を含む層状材料の粒子を含み、
前記層が、以下の式:
MmXn
(式中、Mは、少なくとも1種の第3、4、5、6、7族金属であり、
Xは、炭素原子、窒素原子またはそれらの組み合わせであり、
nは、1以上4以下であり、
mは、nより大きく、5以下である)
で表される層本体と、該層本体の表面に存在する修飾または終端T(Tは、水酸基、フッ素原子、塩素原子および酸素原子からなる群より選択される少なくとも1種である)とを含む、ウイルス不活化物品。 - 前記基材が、フィルター、マスク、フェイスシールド、包帯、手袋、ガウン、タッチパネル、ディスプレイ、フィルムおよびシールからなる群より選択されるいずれかである、請求項12に記載のウイルス不活化物品。
- 前記MmXnが、Ti3C2である、請求項12または13に記載のウイルス不活化物品。
- 前記粒子の厚さの平均値が、10nm以下である、請求項12~14のいずれかに記載のウイルス不活化物品。
- 分散剤、バインダ、酸化防止剤、粘度調整剤および香料からなる群より選択される少なくとも1つの添加剤を更に含む、請求項12~15のいずれかに記載のウイルス不活化物品。
- 前記粒子におけるLiの含有率が、20質量ppm以下である、請求項12~16のいずれかに記載のウイルス不活化物品。
- 前記粒子における塩素と臭素の合計含有率が、1500質量ppm以下である、請求項12~17のいずれかに記載のウイルス不活化物品。
- 前記粒子が、金属および金属酸化物の少なくとも一方を担持している、請求項12~18のいずれかに記載のウイルス不活化物品。
- 前記粒子が、酸化チタンを担持している、請求項12~19のいずれかに記載のウイルス不活化物品。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202180085839.8A CN116615100A (zh) | 2020-12-22 | 2021-12-16 | 病毒灭活液剂和病毒灭活物品 |
JP2022571383A JPWO2022138456A1 (ja) | 2020-12-22 | 2021-12-16 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063129051P | 2020-12-22 | 2020-12-22 | |
US63/129,051 | 2020-12-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022138456A1 true WO2022138456A1 (ja) | 2022-06-30 |
Family
ID=82157745
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2021/046578 WO2022138456A1 (ja) | 2020-12-22 | 2021-12-16 | ウイルス不活化液状剤およびウイルス不活化物品 |
Country Status (3)
Country | Link |
---|---|
JP (1) | JPWO2022138456A1 (ja) |
CN (1) | CN116615100A (ja) |
WO (1) | WO2022138456A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023112778A1 (ja) * | 2021-12-16 | 2023-06-22 | 株式会社村田製作所 | 2次元粒子、導電性膜、導電性ペーストおよび複合材料 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009526828A (ja) * | 2006-02-16 | 2009-07-23 | クイーン メアリー アンド ウェストフィールド カレッジ | 殺ウイルス材料 |
CN111905829A (zh) * | 2020-09-08 | 2020-11-10 | 陈兵 | 一种除病毒用改性Mn掺杂PCN-222@Ti3C2光催化剂及其制备方法 |
-
2021
- 2021-12-16 JP JP2022571383A patent/JPWO2022138456A1/ja active Pending
- 2021-12-16 WO PCT/JP2021/046578 patent/WO2022138456A1/ja active Application Filing
- 2021-12-16 CN CN202180085839.8A patent/CN116615100A/zh active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009526828A (ja) * | 2006-02-16 | 2009-07-23 | クイーン メアリー アンド ウェストフィールド カレッジ | 殺ウイルス材料 |
CN111905829A (zh) * | 2020-09-08 | 2020-11-10 | 陈兵 | 一种除病毒用改性Mn掺杂PCN-222@Ti3C2光催化剂及其制备方法 |
Non-Patent Citations (1)
Title |
---|
UNAL MEHMET ALTAY; BAYRAKDAR FATMA; FUSCO LAURA; BESBINAR OMUR; SHUCK CHRISTOPHER E.; YALCIN SüLEYMAN; ERKEN MINE TURKTAS; OZ: "2D MXenes with antiviral and immunomodulatory properties: A pilot study against SARS-CoV-2", NANO TODAY, ELSEVIER, AMSTERDAM, NL, vol. 38, 18 March 2021 (2021-03-18), NL , XP086616454, ISSN: 1748-0132, DOI: 10.1016/j.nantod.2021.101136 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023112778A1 (ja) * | 2021-12-16 | 2023-06-22 | 株式会社村田製作所 | 2次元粒子、導電性膜、導電性ペーストおよび複合材料 |
Also Published As
Publication number | Publication date |
---|---|
CN116615100A (zh) | 2023-08-18 |
JPWO2022138456A1 (ja) | 2022-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5451622B2 (ja) | 微生物の増殖を制限するための方法 | |
US10399041B2 (en) | Two-dimensional metal carbide antimicrobial membrane and antimicrobial agent | |
Liu et al. | Facile synthesis of monodispersed silver nanoparticles on graphene oxide sheets with enhanced antibacterial activity | |
Zhao et al. | Highly stable graphene-based nanocomposite (GO–PEI–Ag) with broad-spectrum, long-term antimicrobial activity and antibiofilm effects | |
Puspasari et al. | ZnO-based antimicrobial coatings for biomedical applications | |
Pham et al. | Graphene induces formation of pores that kill spherical and rod-shaped bacteria | |
Stanić et al. | Synthesis of antimicrobial monophase silver-doped hydroxyapatite nanopowders for bone tissue engineering | |
WO2022138456A1 (ja) | ウイルス不活化液状剤およびウイルス不活化物品 | |
Zhang et al. | Low Ag-doped titanium dioxide nanosheet films with outstanding antimicrobial property | |
JP5777337B2 (ja) | 抗菌性材料 | |
WO2017083055A1 (en) | Two-dimensional metal carbide antimicrobial membrane and antimicrobial agent | |
Karunakaran et al. | Ascorbic acid-assisted microwave synthesis of mesoporous Ag-doped hydroxyapatite nanorods from biowaste seashells for implant applications | |
ES2341749B1 (es) | Polvo compuesto nanoestructurado fosfato de calcio-plata. procedimiento de obtencion y sus aplicaciones bactericidas y fungicidas. | |
Zhao et al. | Phase transition and morphological evolution of titania/titanate nanomaterials under alkalescent hydrothermal treatment | |
WO2022080321A1 (ja) | 導電性2次元粒子およびその製造方法、導電性膜、導電性複合材料、ならびに導電性ペースト | |
Gupta et al. | Antiviral properties of select carbon nanostructures and their functionalized analogs | |
Calabrese et al. | Antifouling and antimicrobial activity of Ag, Cu and Fe nanoparticles supported on silica and titania | |
Vukomanovic et al. | The growth of silver nanoparticles and their combination with hydroxyapatite to form composites via a sonochemical approach | |
Zhou et al. | A silicon-based antibacterial material featuring robust and high antibacterial activity | |
JP7416289B2 (ja) | 吸着材およびその製造方法、吸着シート、人工透析用分離膜ならびに人工透析機器 | |
AU2021345508A1 (en) | Graphene-silver nanocomposites and uses for same as an antimicrobial composition | |
Hidayat et al. | Antimicrobial air filter made of chitosan-ZnO nanoparticles immobilized on white silica gel beads | |
Salim et al. | Review of modified Zeolites by surfactant and Silver as antibacterial agents | |
John et al. | Synthesis, Characterization and Anti-bacterial Activities of Pure and Ag-doped SnO2Nanoparticles | |
JP5035590B2 (ja) | 機能性材料の製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21910604 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2022571383 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202180085839.8 Country of ref document: CN |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 21910604 Country of ref document: EP Kind code of ref document: A1 |